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ABSTRACT
Cluster Determinant 44 (CD44) Receptor and Gout: Mechanistic Role in Pathogenesis
and Therapeutic Targets
by Emira Bousoik
Gout is considered one of the most common forms of arthritis. It is characterized by
sudden, severe attacks of pain, redness, and swelling in the joints. Management of acute
gout attacks remains suboptimal, and hospitalizations due to poorly controlled flares
have significantly increased over the past two decades. Colchicine is considered one of
the first-line treatments for the relief of the symptoms associated with gout attacks.
However, the use of colchicine for gout therapy has limitations due to the severe
adverse effects, including fatalities. Acute gout is caused by deposition of monosodium
urate (MSU) crystals in peripheral joints and surrounding tissues, which activate the
resident macrophages to produce pro-inflammatory cytokines and consequently leads
to an inflammatory response. The CD44 receptor is highly expressed in macrophages
and plays an essential role in inflammation. The binding of endogenous ligands to
CD44 on the surface of macrophages was shown to result in ligand internalization. In
this project, we aimed to assess the role of CD44 using in vitro models of BMDMs of
different genotypes and used Extra cellular domain shedding to study the impact on
MSU phagocytosis, NF-kB translocation, NLRP3 inflammasome activation, and
proinflammatory cytokine production in human macrophages. We also aimed to study
the role of CD44 in regulating MSU-induced inflammation in a murine peritoneal
model of acute gout. Moreover, we aimed to evaluate the feasibility of conjugating the
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P6 peptide, a 20-amino acid residue peptide that binds to CD44, to Ndeacetylcolchicine via a hydrolyzable linker and study the efficacy and safety of the
colchicine-P6 peptide conjugate in an in vitro model of MSU stimulated macrophages.
our findings establish the CD44 receptor as a promising therapeutic target in gout, both
through inhibition of NFkB pathway activation and modulation of macrophage
phagocytosis of MSU crystals and in facilitating the uptake of small molecules that
have an intracellular target in macrophages.
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Chapter 1: Gout: Overview
History
Gouty arthritis is one of the oldest known diseases in human history. It was first
identified in 2,640 BC by the Egyptians, and in the fifth century BC, it was recognized
by Hippocrates, who referred to it as 'the unwalkable disease’ [1,2]. The term gout was
derived from “gutta”, the Latin word for drop, and referred to the belief that the joint
inflammation experienced during a gouty attack is a result of the dropping of vicious
humor from the patient's blood into the joint. Historically, gout was described as the
'disease of kings.' This is because gout has been associated with the overindulgence of
food and alcohol, which, in the past, only the powerful and affluent could afford [3,4].

Epidemiology
Gout is considered one of the most common types of inflammatory arthritis and a
leading cause of disability, morbidity, and high healthcare usage around the world [5,6].
According to the Global Health Data Exchange (GHDx) and the World Health
Organization (WHO), the incidence and the prevalence of gout have increased during
the last 25 years; moreover, gout mortality is expected to increase by 55% by 2060 [7].
In the US, during the period of 2007–2008 to 2015–2016, the prevalence of gout
increased from 8.3 million to 9.2 million, and it is expected to rise to 10% within the
next few years, due to poor dietary habits, a lack of exercise, and increased incidence
of metabolic syndrome and obesity [8,9].

Risk Factors
There are two types of risk factors for gout:
1. Non-modifiable Risk Factors
1.1.Age
Increasing age is strongly associated with an increased risk of gout. The increased
longevity of populations contributes to a higher prevalence of gout through the
1

disorder's association with age-related diseases, such as metabolic syndrome, diabetes,
and hypertension, as well as with the treatments for these diseases [10,11].
1.2.Sex
Gout is usually considered to be primarily a disease in males. Although gout prevalence
has increased in both sexes, among patients younger than 65 years old, the prevalence
in men is fourfold higher than that in women [10,11]. The reason behind this significant
difference in gout risk in men and women might relate mainly to the uricosuric action
of estrogen. However, in patients older than 65 years, the sex gap narrows to one woman
for every three men with gout, most likely reflecting the loss of the uricosuric effect of
estrogen following the menopause [10,11].
1.3.Genetics
Genetic factors play a significant role in gout. Genome-wide association studies
(GWASs) have identified genetic variants in multiple genes associated with serum uric
acid levels. Glucose transporter type 9 (GLUT-9, also known as SLC2A9), urate anion
transporter 1 (URAT1, also known as SLC22A12), and ATP-binding cassette
subfamily G member 2 (ABCG2) urate transporters play essential roles in mediating
urate excretion and reabsorption, and their gene dysfunctions cause aberrant urate
transport disorders leading to hyperuricemia, which commonly predisposes to gout. A
new study has shown that ABCG2 dysfunction is implicated in gout disease not only
through urate transport disorders but also via augmented IL-1β and IL-8 release
[10,13,14].
2. Modifiable Risk Factors
2.1.Dietary
Several studies have reported that the frequent consumption of alcohol, purine-rich
foods such as red meat and seafood, and foods containing fructose is associated with

2

increased urate concentrations and the risk of developing gout. The ingestion of fructose
increases serum urate levels by generating urate through hepatic metabolism, while
alcohol consumption increases lactic acid, which inhibits the excretion of renal urate.
However, the pathogenetic mechanisms by which these foods influence the risk of gout
are not entirely clear [10,11].
2.2.Chronic Diseases
A number of diseases have been considered as risk factors for gout. Obesity is strongly
linked with a higher risk of gout. It increases serum urate by eliciting both increased
production and reduced renal urate excretion via promoting insulin resistance, which,
in turn, reduces the renal excretion of urate. Moreover, obesity has been shown to
increase systemic inflammation via increasing proinflammatory cytokines, such as
tumor necrosis factor-α and interleukin-6 [11]. Hypertension and cardiovascular
diseases have a strong association with gout incidences. Individuals with hypertension
and congestive heart failure have a twofold and fourfold higher risk of developing gout,
respectively. This potentially results from the use of diuretics, beta-blockers, and alpha1 blockers, which reduce the glomerular filtration rate and raise serum uric acid (UA)
levels [11,17]. Patients with HIV infection are at an increased risk of gout. This is
probably because of the use of antiretroviral drugs causing metabolic disturbance and
hyperuricemia [12]. Patients suffering from type II diabetes (T2D) have a higher risk
of gout. A recent study showed that the serum uric acid levels are higher in patients
with T2D due to an increase in insulin resistance, which reduces the clearance of uric
acid (15). The increased risk is not only caused by diabetes itself, but also by the
presence of comorbidities in type II diabetic patients, such as reduced renal function
and hypertension [15]. Patients with chronic renal disease and kidney transplant
recipients may develop increased levels of UA due to decreased elimination, which
predisposes them to the development of gout. Medications that are commonly
prescribed to transplant recipients, including diuretics, antimicrobials such as
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ethambutol and ketoconazole, and immunosuppressive drugs such as cyclosporin and
tacrolimus are strongly associated with hyperuricemia and gout [11,16,17].
Several studies have suggested that the relationship between gout and these diseases is
bidirectional, which means, for example, that patients with kidney disease are at a high
risk of gout, and vice versa. However, there is still not enough convincing evidence
regarding this [18,42].
2.3.Medications
In addition to the drugs mentioned above, anti-tuberculosis drugs such as pyrazinamide,
and low-dose aspirin are among the drugs that are known to increase the risk of gout,
by increasing serum UA levels through increased uric acid reabsorption and decreased
uric acid secretion [11,16,17]. Moreover, several chemotherapy drugs have been shown
to increase the risk of developing gout by increasing serum uric acid levels.
Chemotherapy drugs can cause tumor lysis syndrome (TLS), an oncologic emergency.
TLS is caused by massive tumor cell lysis with the release of intracellular material into
the systemic circulation. The release of cellular nucleic acids and purine nucleotides by
these drugs causes an increase in UA production that leads to a marked increase in
serum uric acid levels. Hyperuricemia induced by these drugs is considered to be the
most serious type of drug-induced hyperuricemia [16].

Pathophysiology
Gout progresses through four pathophysiological stages, from the silent buildup of UA
in the blood to chronic arthritis. However, the progression from one stage to the other
is not inevitable.
1. Hyperuricemia
UA is a weak acid with dual pKas of 5.4 and 9.8. Under normal physiologic conditions
(pH 7.4 and 37°C), it exists in its ionized form as urate. UA is the end product of both
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endogenous (~300–400 mg) and exogenous (~300 mg) purine metabolism. It is
synthesized mainly in the liver, intestines, and vascular endothelium from exogenous
purine metabolism (dietary sources) and endogenously via the degradation of
nucleic acids, adenine, and guanine from damaged and dead cells. About two-thirds of
the daily UA pool is filtrated by the glomerulus in the kidneys. However, most of this
amount is reabsorbed in the proximal renal tubule, and only 10% of filtered urate is
cleared via urine. The other one-third of the UA pool is secreted in the gastrointestinal
tract, where UA can be further metabolized by resident gut bacteria via a process called
intestinal uricolysis. Both overproduction of UA and its underexcretion lead to
hyperuricemia, abnormally elevated levels of serum urate (>6.8 mg/dL) [19-22,29,33].
2. Monosodium Urate Crystal Formation
Three key steps are required for monosodium urate crystal formation: reduced urate
solubility, crystal nucleation, and crystal growth. An elevated urate concentration is a
central factor driving all three stages [23].
In addition to the high level of urate, sodium ions, damaged cartilage, and temperature
are other factors that play a role in monosodium urate crystal formation through their
effects on urate solubility. The solubility of urate decreases when the concentration of
sodium ions increases; urate molecules combine with sodium ions and form the less
soluble salt form, monosodium urate (MSU). Increased concentrations of chondroitin
sulfate and the degradation of protein-polysaccharide complexes as a result of damaged
cartilage have been shown to enhance MSU crystal formation through reduced urate
solubility. It has been reported that a reduction in temperature from 37°C to 35°C can
cause a decrease in the solubility point of urate from 6.8 to 6.0 mg/dL. This explains
why the first metatarsophalangeal joint that is exposed to sustained cooler temperatures
is the most common site for gouty attacks [23-26,29].
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In the nucleation step, MSU molecules gather into clusters that reach a critical mass
and become stable; then, these clusters aggregate further to form crystal nuclei, the
basis for new crystal formation. Nucleation is enhanced by acidification, increased
calcium ions concentration, and local trauma. Acidification also indirectly enhances
MSU crystal nucleation by increasing calcium ion activity, which significantly
potentiates urate nucleation. A low pH increases the amount of calcium ions present in
the serum by reducing their binding to macromolecules and phosphates. Local trauma
can directly lead to MSU crystal nucleation and also to it indirectly by lowering
synovial pH. In the growth step, fully aggregated MSU crystals are formed. The rate of
MSU crystal growth over time is mainly dependent on the level of urate [23-26,29].
3. Acute Gout Attacks
An acute gout attack is characterized by the sudden onset of severe pain, redness, and
swelling of a joint. It usually involves a single joint, but occasionally involves two or
more joints [34]. An acute gout attack is an acute inflammatory reaction that arises in
response to the interaction of MSU crystals with resident macrophages in the joint.
MSU-induced inflammation is a two-step process: priming and activation (Figure 1-1).
The first signal, known as the priming step, is regulated by pattern-recognition receptors
(e.g., Toll-like receptors (TLRs)), which activate the transcription factor NF-κB. The
activated NF-κB, in turn, induces the expression of NACHT, LRR and PYD domainscontaining protein 3 (NLRP3) inflammasome components and proinflammatory
cytokines, such as precursors of IL-1β and IL-8. The NLRP3 inflammasome is a
macromolecular complex that consists of NLRP3, Apoptosis-associated speck-like
protein containing a CARD (ASC), and procaspase-1, which are not constitutively
expressed in resting macrophages. The second signal, the activation step, is triggered
by MSU crystals. When resident macrophages engulf MSU crystals, they form
phagosomes in the cytosol, which fuse with lysosomes and form phagolysosomes. This
event causes lysosomal damage, resulting in leakage of lysosomal contents into the

6

cytosol. The release of lysosomal contents, including cathepsins (cath) B and L, directly
activates the NLRP3 inflammasome. The internalization of MSU crystals also leads to
the generation of reactive oxygen species (ROS) through the activation of NADPH
oxidases. ROS activate the NLRP3 inflammasome. The phagocytosis of MSU can also
induce adenosine triphosphate (ATP) secretion, which in turn activates P2X7 receptor.
Upon activation of the P2X7 receptor, there is a rapid efflux of intracellular potassium
that stimulates NLRP3 inflammasome activation. This leads to the activation of
caspase-1, which, in turn, cleaves IL-1β and IL-8 precursors to their active forms, and
they are then secreted from the cell into the extracellular environment. In turn, the
secretion of these cytokines promotes the infiltration of neutrophils and monocytes into
the joint. The interaction of these infiltrated cells with the MSU crystals heightens
inflammation leading to the escalation of the condition [27-30,33].

Figure 1-1
MSU-induced inflammation is a two-step process: The first priming step (signal 1) is initiated by danger signals and
pathogen-associated molecules (LPS: lipopolysaccharide) and cytokines (IL-1β and TNFα) that signal through
pattern-recognition receptors to activate NF-ƘB mediated upregulation of NLRP3 and proinflammatory cytokines
expression. The activation step (signal 2) is triggered by MSU crystals. The internalization of MSU crystals leads to
lysosomal disruption and ROS and ATP generation, which initiates NLRP3 inflammasome component (NLRP3;
ASC; Pro-caspase-1) assembly and activation of pro-caspase-1 to cleave pro-IL-1β and pro-IL-18 to their active
forms.
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4. Advanced Gout
Over time and with insufficiently treated hyperuricemia, acute gout may develop into
chronic tophaceous gout. However, the mechanisms by which chronic tophaceous gout
is developed are not entirely understood. Chronic gout is characterized by the formation
of tophi in joints, soft tissues, or skin, which consist of MSU crystal-NET masses,
mono- and multinucleated phagocytes such as giant cells, and fibroblasts. The
infiltration of tophi into bones can cause bone erosion and joint damage. Matrix
metalloproteinase enzymes and bone-resorptive osteoclasts are produced locally within
tophi, which leads to progressive bone erosion. Moreover, the high levels of
proinflammatory cytokines that arise during gout flares may contribute to bone damage
[29,31-33].

Management of Gout
There are three stages in the management of gouty arthritis: control of the acute attack,
control of hyperuricemia, and providing prophylaxis to prevent the repetition of acute
attacks. However, a study that was carried out on 575 gout patients showed that the
majority of gout patients have strong contraindications to at least one of the usually
used gout medicines [35,41].
1. Management of Acute Attacks
Colchicine and nonsteroidal anti-inflammatory drug (NSAIDs) are considered as firstline treatments for the relief of the symptoms associated with flares of gout. In the US,
indomethacin, sulindac, and naproxen are the only NSAIDs approved for the
management of acute gouty arthritis pain. NSAIDs can treat acute gout by reducing
inflammation through several mechanisms, including the inhibition of cyclooxygenase.
Since NSAIDs have been associated with an increased risk of gastrointestinal
ulcerations, myocardial infarctions, stroke, and heart failure, and they interact with
antihypertensive medications, as well as exacerbating renal dysfunction, their usage is
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contraindicated in patients with these comorbidities [35]. Colchicine is more beneficial
in patients with cardiovascular diseases. Intravenous forms of Colchicine are no longer
approved by the US Food and Drug Administration (FDA) due to adverse effects,
including fatalities and currently only oral formulations of colchicine can be used for
treating gout. Since colchicine is metabolized by the cytochrome P450 3A4 (CYP3A4)
enzyme and excreted via the P-glycoprotein (P-gp) transport system, its use is
contraindicated in patients with renal or hepatic dysfunctions, especially those who are
taking P-gp or CYP3A4 inhibitors. Colchicine affects acute inflammation associated
with gout in a multimodal manner. Colchicine inhibits the assembly of NALP3 with
ASC and the generation of ROS, which are necessary for NALP3 inflammasome-driven
caspase-1 activation, and thereby blocks the release of proinflammatory cytokines and
chemokines. This effect likely occurs via the inhibition of microtubule and impaired
phagocytosis and the transport of MSU crystals to the lysosome [34-37,39].
Glucocorticoids are good alternatives for patients with several comorbidities and who
cannot receive NSAIDs or colchicine. Oral, intra-articular, intra-muscular, and
intravenous corticosteroids can all be effective in the management of acute gout
attacks. Intra-articular corticosteroids are beneficial if only one or two joints are
affected and in patients who cannot receive oral therapy. Oral glucocorticoids, such as
prednisone, are useful when multiple joints are affected, or the joints are not amenable
to injection. Since glucocorticoids promote glucose production in the liver and reduce
the sensitivity of the cells to insulin, they should be used with caution in those with
diabetes [34-37,39].
Canakinumab, a fully human monoclonal antibody selectively inhibiting IL-1β, has
been approved by the FDA for the treatment of systemic juvenile idiopathic arthritis. It
works by blocking IL-1β signaling, resulting in inflammation suppression. Several
studies have demonstrated the efficacy of these drugs in patients with gout for whom
conventional therapies are contraindicated or ineffective. In 2013, canakinumab was
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approved by the European medicines agency for the symptomatic treatment of adult
patients with frequent gouty arthritis attacks. FDA has not yet approved canakinumab
for acute gout, and further studies are required to determine the risk–benefit ratio of this
agent. Infections and injection site reactions are the most well-known adverse effects
associated with canakinumab [35-37,39].
Anakinra, a recombinant, nonglycosylated form of the human IL-1 receptor antagonist,
has been approved for use in rheumatoid arthritis. Although not an FDA-approved
indication, anakinra is sometimes used off-label to treat gout flares in patients for whom
conventional therapies are contraindicated or do not provide an adequate res European
Medicines Agency
ponse [37,39].
2. Management of Hyperuricemia
Urate-lowering therapies (ULTs) are required to reduce and maintain serum UA (sUA)
below saturation levels. The maintained lowering of sUA reduces MSU crystal
formation, decreases the incidence of gout flares, and promotes tophus
resolution. Xanthine oxidase inhibitors and uricosurics are the most widely used ULTs
for reducing serum urate levels in patients with gout [35,37,39].
Xanthine oxidase inhibitors are considered first-line ULTs in patients with gout.
Xanthine oxidase is an enzyme involved in the purine metabolism pathway that
converts hypoxanthine into UA. Therefore, xanthine oxidase inhibitors can be useful
for patients who both overproduce and under-excrete UA. Allopurinol and febuxostat
are considered the primary options in this class [34,35,37,39].
Uricosurics are usually considered second-line therapy ULTs. Probenecid and
benzbromarone are considered the primary options in this category. Uricosurics work
by increasing the renal clearance of UA, typically through inhibiting the proximal
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tubular reabsorption of UA in the kidney. Uricosurics can be considered for use in
combination with xanthine oxidase inhibitors; however, they should not be used in
patients who have gout based on the overproduction of UA. Lesinurad, a selective UA
reabsorption inhibitor, is the latest uricosuric agent to be approved by the FDA. Using
lesinurad as a monotherapy can increase the risk of acute renal failure. Therefore, it is
only indicated as adjunctive therapy in combination with xanthine oxidase inhibitors
[35-37,39].
Pegloticase is a mammalian recombinant uricase. Uricase is an enzyme that converts
UA into allantoin, the more soluble form. Pegloticase is approved for the management
of chronic gout in patients in whom conventional ULTs are ineffective [35-37,39].
3. Gout Flare Prophylaxis
One of the challenges in managing gout is that ULTs may increase the incidence of
gout flares. This is probably due to the mobilization of MSU crystals; however, the
exact mechanism is not clear. Because of this paradoxical relationship, prophylaxis with
either low-dose colchicine or NSAIDs has been recommended to be used during the
early months of urate-lowering treatment [38,40].
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Chapter 2: Cluster Determinant 44 (CD44) Overview

Cluster Determinant 44 (CD44) Receptor Family
CD44 is a family of non-kinase, single-span transmembrane glycoproteins belonging
to the class of cell adhesion molecules (CAMs). It was first discovered as a molecule
present on the surface of lymphocytes. Then, it was rediscovered as phagocytic
glycoprotein 1 (Pgp-1) expressed on the surface of most mammalian cells [1-3].

CD44 Isoforms
CD44 is encoded by one gene located on chromosome 11 in humans and chromosome
2 in mice, and it has a molecular weight of 85–200 kDa. The CD44 gene is comprised
of 19 exons in humans and 20 in mice, which encode multiple CD44 isoforms. The first
five (1–5) and the last five exons (15–19) are constant and encode the shortest isoform
of CD44 (85–95 kDa), known as CD44 standard (CD44s), whereas the middle nine
exons (exons 5a–14; v1–v10) can be alternatively spliced and assembled with the ten
exons contained in the CD44 standard isoform and encode CD44 variant isoforms
(CD44v). CD44s, also known as hematopoietic CD44 (CD44H), is the highly expressed
CD44 isoform. CD44v may contain one or more variant regions, such as CD44v6 or
CD44v3–v7. CD44v isoform expression is mainly restricted to epithelial cells, tumor
cells, and activated lymphocytes [2-4].

Structure of CD44
CD44 consists of three major domains: the extracellular domain, the transmembrane
domain, and the cytoplasmic (intracellular) domain. The extracellular domain, encoded
by exons 1–16, interacts with the external microenvironment and senses stimuli in it.
The transmembrane domain, encoded by exon 17, provides an avenue for interacting
with co-factors and adaptor proteins. The intracellular domain, encoded by exons 18–

15

19, has a short-tail and long-tail configuration with functions in nuclear localization and
transcription mediation[1-4].

CD44 Ligands
The major ligand of CD44 is hyaluronic acid (HA). HA, a linear polymeric
glycosaminoglycan, is a ubiquitous component of the extracellular membrane. All
isoforms of CD44 possess an HA-binding domain located in the N-terminal region of
the extracellular domain. CD44 binding to HA depends on the activation state of CD44.
Three states of CD44 activation have been defined: active, constitutive binding to HA,
inducible, non-binding to HA unless activated by physiological stimuli, and inactive,
non-binding to HA. HA binding to CD44 leads to conformational changes favoring the
binding of adaptor molecules to the intracellular cytoplasmic tail of CD44, leading to
cell signaling that enhances cellular function, including cell adhesion and migration.
CD44 can also interact with several other ligands, including growth factors such as
osteopontin (OPN), matrix metalloproteinases (MMPs), and collagen. The interaction
between CD44 and its ligands is dependent on the type of CD44 isoform, as well as its
post-translational modifications, including both N- and O-linked glycosylation and the
attachment of glycosaminoglycans, and these modifications can be varied according to
different physiological stimuli [1,3,5].

The Role of CD44 in Inflammation
CD44 can act as a pro- and anti-inflammatory molecule; the domination of either one
is based on the disease, organ, and the type of immune response evoked [6,7] (Figure11).
1. The Proinflammatory Roles of CD44
During inflammation, CD44 plays a vital role in leukocyte extravasation, the
emigration of leukocytes from the blood through vascular endothelium into inflamed
tissues. Extravasation involves four stages: rolling/tethering, cell activation, firm
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adhesion, and transmigration. At sites of inflammation, endothelial cells become
activated, express endothelial selectins (E- and P-selectins), and increase the expression
of CD44 and HA on endothelial cells in response to inflammatory cytokines. T-cell
rolling on inflamed endothelium can be mediated by an interaction between CD44 on
activated T cells with HA presented by CD44 on activated endothelial cells [6-9]. In
addition to interaction with HA, CD44-dependent rolling can also occur through
binding to endothelial selectins, E-selectins. In addition to its role in the rolling step,
CD44 is also required for the firm adhesion of T cells mediated by the 41 integrin
(VLA-4). CD44 associates with VLA-4 in the membrane of activated T cells through
its cytoplasmic tail. The association between CD44 and VLA-4 not only allows for firm
adhesion but also provides each with access to the other’s signaling pathways, which
otherwise would not be available [6,10,11]. Moreover, chemokines, such as MIP-1, can
bind to the proteoglycan side chains of endothelial cell CD44; this promotes T-cell
adhesion. Endothelial cell CD44 and HA can also contribute to neutrophil recruitment
to the site of the inflammation. CD44 plays an essential role in the adhesion of
neutrophils to the endothelium, and it also mediates the transmigration of neutrophils
across

the

venular

endothelium

[12,13].

CD44

is

also

implicated

in

monocyte/macrophage recruitment to sites of inflammation. However, the contribution
of CD44 to monocyte/macrophage recruitment varies depending on the inflammatory
stimuli or the inflamed tissue [6,7,14,15].
CD44 can also promote inflammation through the induction of inflammatory gene
expression. Engagement of CD44 induces expression and the production of cell
adhesion molecules, inducible nitric oxide synthase, and the releasing of inflammatory
mediators, including cytokines and chemokines in both infiltrating leukocytes and
parenchymal cells. CD44 can also act as an activation molecule by stimulating cell
proliferation and migration in a variety of cells, such as epithelial cells, fibroblasts, and
endothelial cells [6,7,17].
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Several signaling pathways are implicated in CD44 mediated cellular function during
inflammation. The ligation of CD44 leads to the degradation of IkB and the activation
of NF-KB; however, the signaling pathways upstream of NF-KB are not well studied.
Moreover, CD44 engagement also leads to tyrosine phosphorylation and the activation
of Src family protein tyrosine kinases. Moreover, it mediates the activation of MAPK,
PI3K, PLC, Ras, and PKCg [6,7,16].
2. The Anti-Inflammatory Roles of CD44
CD44 contributes to the resolution of an inflammatory response via promoting the
phagocytosis of infiltrating leukocytes and the uptake of fragmented HA, thus downregulating TLR-4 signaling in macrophages. Transforming growth factor (TGF-1) has
a critical role in the downregulation of the inflammatory response via phagocytosis of
apoptotic neutrophils, apoptotic cells, and the cellular debris and clearance of HA
fragments, which cause inflammation through the activation of TLR-2 and TLR-4.
Matrix metalloproteinase 9 (MMP9) and CD44 interaction mediates cleavage and the
activation of TGF-1[18-21]. Moreover, CD44 and HA are implicated in activationinduced cell death (AICD), a process that is responsible for the removal of activated T
cells and the maintenance of immune homeostasis. Although AICD is mainly regulated
by the Fas receptor, CD44 mediates AICD by a Fas-independent mechanism [22,23].

Figure 2-1
The Role of CD44 in Inflammation: A) The proinflammatory roles of CD44. B) The Anti-Inflammatory roles of
CD44
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CD44 as a Therapeutic Target
Data from the numerous in vivo studies using different inflammatory disease models
reported that CD44 could either enhance or diminish the severity of inflammation,
depending upon the disease model. The inflammatory role of CD44 was studied in an
atherosclerosis mouse model, and the data showed that CD44 promotes the progression
of atherosclerosis through augmenting the number of macrophage and T cells
trafficking to the site of inflammation [15, 24]. The impact of anti-CD44 mAb (IM7)
causes the shedding of CD44 and has been studied in mouse models of several
autoimmune diseases, including rheumatoid arthritis, multiple sclerosis, and chronic
uveitis. The studies reported that IM7 treatments reduce the severity of these diseases
and prevent disease relapse. The ability of IM7 treatments to reduce disease severity in
each of these models is due to their ability to inhibit leukocyte recruitment to the
inflammatory sites [25, 26].
The role of CD44 in acute lung and hepatic inflammations was studied in mouse models
using CD44 knockout mice. In the bleomycin-induced lung inflammation model, CD44
deficiency resulted in a reduction in TGF-1 activation, the impaired removal of
apoptotic neutrophils, and the accumulation of HA fragments [19]. In the second lung
inflammation model, lipopolysaccharide (LPS) was used to induce lung inflammation,
and the absence of CD44 led to increased chemokine expression, leukocyte infiltration,
and NF-kB activity in lung tissue [27]. In the superantigen (SEB)-induced liver injury
model, CD44 deficiency led to an augmentation in leukocyte recruitment, a reduction
in AICD, and an increase in the severity of hepatitis, while using IM7 AB in the same
model enhanced liver damage [28].
Accumulating evidence suggests that CD44 is a potential therapeutic target for several
inflammatory diseases. However, to the best of our knowledge, no therapies have been
developed yet focusing on the important of CD44 in the resolution of inflammation in
gout.
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Overall Hypothesis and Specific Aims
Overall Hypothesis
CD44 mediates MSU phagocytic uptake by macrophages and CD44 receptor
neutralization and/or deficiency reduces crystal uptake, NFkB and NLRP3
inflammasome activation and suppresses MSU linked inflammation.
Specific Aims
I.

To investigate the role of the CD44 receptor in modulating MSU crystal uptake

and associated NLRP3 inflammasome priming and activation in human macrophages
in response to MSU danger signals. (Chapter 3)
II.

To investigate the role of CD44 receptor in the pathogenesis of crystal-induced

inflammation in vivo and provide a proof-of-concept for systemic functional blockade
of CD44 receptor as a novel treatment strategy for acute gout. (Chapter 3)
III.

To evaluate the feasibility of conjugating the P6 peptide, a 20-amino acid

residue peptide that binds to CD44, to N-deacetylcolchicine via a hydrolyzable linker
and study the efficacy and safety of the colchicine-P6 peptide conjugate in an in vitro
model of MSU stimulated macrophages. (Chapter 4)
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Chapter 3: CD44 Receptor Mediates Urate Crystal Phagocytosis by
Macrophages and Regulates Inflammation in A Murine Peritoneal
Model of Acute Gout
Abstract
Gout is a chronic arthritis caused by deposition of poorly soluble monosodium urate
monohydrate crystals (MSU) in peripheral joints.

Resident macrophages initiate

inflammation in response to MSU mediated by NF-kB nuclear translocation and
NLRP3 inflammasome activation. We investigated the role of CD44, a transmembrane
receptor, in mediating MSU phagocytosis by macrophages. We used an antibody that
sheds the extracellular domain (ECD) of CD44 to study the role of the receptor and its
associated protein phosphatase 2A (PP2A) in macrophage activation. We also studied
the significance of CD44 in mediating MSU inflammation in vivo. Cd44-/- BMDMs
showed reduced MSU phagocytosis, LDH release, IL-1β expression and production
compared to Cd44+/+ BMDMs. Elevated CD44 staining was detected intracellularly
and CD44 colocalized with α-tubulin as a result of MSU exposure and ECD-shedding
reduced MSU phagocytosis in human and murine macrophages. Anti-CD44 antibody
treatment reduced NF-kB p65 subunit nuclear levels, IL-1β expression, pro-IL-1β and
IL-8 production in MSU stimulated THP-1 macrophages (p<0.01). The effect of antiCD44 was mediated by an enhancement in intracellular PP2A activity. CD44 ECDshedding reduced the conversion of procaspase-1 to active caspase-1, reduced active
caspase-1 activity and resultant generation of mature IL-1β in MSU-stimulated
macrophages. Neutrophil and monocyte influx and upregulated production of IL-1β
was evident in wildtype mice.

MSU failed to trigger neutrophil and monocyte

recruitment in Cd44-/- mice and lower IL-1β levels were detected in peritoneal lavages
from Cd44-/- mice (p<0.01). Anti-CD44 treatment reduced neutrophil and monocyte
recruitment and resulted in reduced peritoneal lavage IL-1β levels in the same model.
CD44 plays a biologically significant role in mediating MSU macrophage uptake and
downstream inflammation and is a novel target in gout treatment.
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Introduction
Gout is a prevalent form of chronic arthritis characterized by intermittent episodic acute
flares that commonly occurs in peripheral synovial diarthrodial joints due to the
deposition of poorly soluble sodium urate crystals [1-5]. Gout sits at the intersection
of a number of chronic inflammatory and metabolic diseases and is associated with
increased incidence of type-2 diabetes, hypertension, hyperlipidemia, chronic kidney
disease and osteoarthritis [6-10]. The prevalence of gout has been steadily increasing
and refractory, difficult-to-treat gout has been reported in more than 1% of all patients
and is characterized by the presence of ongoing active disease despite the use of
antiinflammatory and urate lowering therapy [11, 12]. Furthermore, management of
acute gout flares remains suboptimal and hospitalizations due to poorly controlled
flares have significantly increased over the past two decades [13-16]. Coupled with
severe toxicities reported with high-dose colchicine and other antiinflammatory drugs,
there is a growing need to identify novel pharmacologic targets to control inflammation
in acute gout flares [17-19].
In response to urate crystals, joint resident macrophages initiate inflammation through
crystal phagocytosis and production of interleukin-1 beta (IL-1β) and other chemokines
[5, 20, 21]. The exact mechanism of crystal phagocytosis by joint macrophages is not
entirely understood. The toll-like receptors (TLRs) family, particularly TLR2 and
TLR4, were thought to mediate urate crystal phagocytosis as part of an innate immune
response in the joint [22]. TLR2 and TLR4 deficient macrophages exhibited reduced
urate crystal phagocytosis and downstream IL-1β production [22]. However, in a
subsequent study, the finding that TLR1 through 9-deficient mice lacked an
inflammatory response in an in-vivo model of gout has challenged the role of TLRs in
gout pathogenesis [23]. In a recent study, we have shown that recombinant human
proteoglycan-4 (rhPRG4) reduced urate crystal phagocytosis by macrophages,
inhibited nuclear factor kappa b (NF-kB) pathway, NOD-, LRR- and pyrin domain-
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containing protein 3 (NLRP3) inflammasome activation, and suppressed IL-1β
expression and secretion [24]. PRG4 is a mucinous glycoprotein that is a major
component of synovial fluid, where it fulfills lubricating and joint homeostatic roles
[25]. PRG4 was recently identified as a cluster determinant-44 (CD44) ligand where it
has an anti-inflammatory role in the joint and an ability to regulate TLR2 and TLR4
receptor stimulation [26-29].

The contribution of CD44 versus TLR2 or TLR4

receptors to the observed efficacy of rhPRG4 in preventing urate crystal phagocytosis
by macrophages was further studied [24]. PRG4 was shown to bind preferentially to
macrophage CD44 compared to TLR2 or TLR4 receptors, which may suggest that
CD44 is implicated in urate crystal phagocytosis by macrophages [24].
CD44 is a transmembrane highly glycosylated receptor with various isoforms generated
by extensive alternative splicing and posttranslational modifications, and is widely
expressed in immune and connective tissue cells [30]. CD44 contributes to the
reception of a broad array of microenvironmental signals including its own ligands,
cytokines and growth factors [31]. CD44 functions to regulate the activation of TLRs
[32-34]. In a recent study, we have shown that with using either a CD44 ligand, e.g.
hyaluronic acid or an antibody that induces the shedding of CD44 extracellular domain
(ECD), agonist-induced TLR2 activation was suppressed in macrophages [34]. HAinduced CD44 receptor internalization or antibody-mediated ECD shedding reduced
NF-kB nuclear translocation leading to attenuation of tumor necrosis factor alpha
(TNF-α) expression [34]. CD44 was shown to be coupled to intracellular protein
phosphatase-2 A (PP2A) activation, where inhibition of PP2A activity reversed the
antiinflammatory effect of the anti-CD44 antibody [34].
The aim of this investigation was to evaluate the singular role of CD44 receptor in
facilitating urate crystal phagocytosis by macrophages and study its function in
regulating downstream NFkB and NLRP3 inflammasome activations and IL-1β
production in-vitro and in-vivo using a peritoneal model of acute gout.
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We

hypothesized that CD44 mediates urate crystal phagocytosis by macrophages and CD44
receptor neutralization and/or deficiency reduces crystal phagocytosis, NFkB and
NLRP3 inflammasome activation and suppresses urate crystal-linked inflammation.

Materials and Methods
Generation of bone marrow derived macrophages (BMDMs) from Cd44+/+ and
Cd44-/- mice and study of macrophage phagocytic activity against latex beads and
urate crystals, crystal-induced cytotoxicity, IL-1β expression and production
studies
Cd44+/+ (JAX stock # 00664) and Cd44-/- (JAX stock # 005085) pathogen-free male
mice (n=15 in each group) were acquired from the Jackson Laboratory (Maine, USA)
[35]. Animals (12-14 weeks old) were euthanized under CO2 and isolation and culture
of BMDMs was performed as described [34, 36]. Differentiation into BMDMs was
confirmed using flow cytometry [34]. All animal experiments were approved by the
IACUC committee at Chapman University.
Generic phagocytic activity of Cd44+/+ and Cd44-/- BMDMs was determined using a
Phagocytosis Activity Assay Kit (IgG FITC) (Cayman Chemicals). Briefly, Cd44+/+
and Cd44-/- BMDMs were seeded in 6 well plates (500,000 cells per well) and allowed
to adhere overnight. Latex bead rabbit IgG -FITC complex was added to the culture
medium at a 1:100 dilution and incubated at 37 °C for four hours. Cells were
subsequently washed twice with the assay buffer. To distinguish cells that have
internalized the beads from those binding the beads at the surface, cells were incubated
with a trypan blue quenching solution for two minutes. Cells were then washed twice
with the assay buffer. Finally, cells were gently scraped and cell-associated
fluorescence intensities were determined using flow cytometry.
Urate crystal phagocytosis by Cd44+/+ and Cd44-/- BMDMs was performed by seeding
BMDMs onto coverslips in 6 well plates (500,000 cells per well) followed by
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incubation with pyrogen-free monosodium urate (MSU) crystals (100μg/ml; Invivogen,
USA) for 4 hours at 37oC. Subsequently, cells were fixed using 4% paraformaldehyde
followed by washing with PBS. Following permeabilization with 0.1% Triton X-100
and washing with PBS, fluoroshield-mounting medium with DAPI (Abcam) was added
and incubated over night at room temperature. BMDMs were visualized under the
microscope and the percentage of cells from each genotype that had intracellular MSU
crystals were determined by a blinded investigator. A total of at least 100 cells over 45 fields were examined across five independent experiments.
To investigate the impact of MSU crystals on Cd44+/+ and Cd44-/- BMDMs cell
viability, we assayed lactate dehydrogenase (LDH) activity levels in culture
supernatants using an LDH Cytotoxicity Assay Kit (Abcam).

BMDMs of both

genotypes (500,000 cells per well) were treated with MSU (100 μg/ml) for 1 and 4
hours followed by collection of culture supernatants, centrifugation at 600x g for 10
min and determination of LDH activity.
To study the stimulation of Cd44+/+ and Cd44-/- BMDMs by MSU crystals or
lipopolysaccharide (LPS; Invivogen), cells were seeded in 6 well plates (500,000 cells
per well) and treated with MSU (100 μg/ml) or LPS (100 ng/mL) for 6 and 72 hours,
respectively. Total RNA extraction, quantification, cDNA synthesis and quantitative
PCR (qPCR) were performed for the MSU stimulation experiment as described [34].
Genes of interest included IL-1b (Mm00434228_m1; ThermoFisher Scientific). The
cycle threshold (Ct) value of IL-1b was normalized to the Ct value of GAPDH
(Mm99999915_g1; ThermoFisher Scientific) in the same sample, and the relative
expression was calculated using the 2-ΔΔCt method [37]. Data are presented as fold
target gene expression compared to untreated control. IL-1b media concentrations
following MSU or LPS stimulations were determined by ELISA (R&D Systems).
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Differentiation of human THP-1 monocytes into macrophages and studies of
comparative MSU phagocytosis against non-phagocytic MCF7 cells, timedependent CD44 expression, crystal phagocytosis and receptor internalization
THP-1 monocytes (ATCC, USA) were differentiated into macrophages by incubation
with phorbol 12-myristate-13-acetate (PMA; Sigma Aldrich) to a final concentration of
5 ng/ml for 48 hours [38]. Subsequently, media supernatants were removed, and wells
were washed with sterile PBS to remove any unattached cells and new RPMI 1640
media was added.
To further validate MSU phagocytosis by THP-1 macrophages, we have compared
MSU crystal phagocytosis by THP-1 macrophages and the non-phagocytic MCF7
breast carcinoma cells (ATCC) [39]. THP-1 and MCF7 cells were seeded in 4-well
chamber slides (250,000 cells per well; ThermoFisher Scientific) and were stimulated
with MSU crystals (100µg/ml) for 4 hours at 37oC followed by washing with PBS.
Direct visualization of MSU crystals under the microscope was performed as described
above.

Indirect assessment of MSU phagocytosis was determined by analyzing

changes in cell side-scatter due to crystal phagocytosis using a flow cytometer (BD
FACSVerse) as described [24]. Two regions of interest were identified; P1 representing
the macrophage population in the absence of MSU exposure and P2 representing the
macrophage population with increased side scatter due to MSU phagocytosis. MSU
positive cells were calculated as the ratio of cells in the P2 region to sum of cells in the
P1 and P2 regions. This indirect method of determining MSU phagocytosis was
previously validated by our group against the direct method of intracellular crystal
visualization [24]. MSU crystal phagocytosis by THP-1 macrophages was recorded
over a 4-hour incubation period.
Time-dependent changes in CD44 expression and soluble CD44 media concentrations
were determined following incubation of THP-1 macrophages with MSU crystals.
THP-1 macrophages (500,000 cells per well) were treated with MSU crystals
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(100μg/ml) for 3, 6, 12 and 24 hours followed by media collection and cell harvest to
perform CD44 gene expression studies as described above using the following
commercially available primers and probes for CD44 (Hs01075864_m1) and GAPDH
(Hs03929097_g1) (ThermoFisher Scientific). In another set of experiments, THP-1
macrophages were incubated with MSU crystals as above followed by cell and
determination of cell-surface CD44 receptor density.
THP-1 macrophages were incubated with an anti-CD44 antibody (Abcam) (1 μg per 1
× 106 cells) for 1 hour at 4 °C. Following cell pelleting and washing with PBS, cells
were subsequently incubated with DyLight® 488 goat anti-mouse IgG at 1:200 dilution
for 30 min at 4 °C. Following cell pelleting and washing, 4% paraformaldehyde
(500 μL) was added and cell-associated fluorescence was determined by flow
cytometry. Soluble CD44 receptor concentrations were determined using an ELISA kit
(R&D Systems).
CD44 receptor internalization following incubation of THP-1 macrophages with MSU
crystals was determined using confocal microscopy and determination of intracellular
CD44 fluorescence intensity. THP-1 macrophages were seeded in 4 well chamber
slides (ThermoFisher Scientific) followed by incubation with MSU crystals (100μg/ml)
for 3 or 6 hours. Subsequently, cells were fixed using 4% paraformaldehyde for 10 min
followed by washing with PBS and permeabilization with 0.1% Triton X-100.
Following washing with PBS, cells were blocked for 30 min in 2% bovine serum
albumin (BSA) in PBS. Cells were incubated with anti-CD44 antibody (1:500 in 2%
BSA; Abcam) overnight at 4oC. Following washing with PBS, FITC-conjugated
secondary antibody (1:1,000; Abcam) and anti-a tubulin monoclonal antibody, Alexa
Fluor 647 (1:1,000; Abcam) were added for two hours. Nuclear staining was performed
using DAPI. Confocal imaging, Z-stacking and colocalization of CD44 and a-tubulin
were performed as described [24]. At least 100 cells were examined in each group
across three independent experiments and data are presented as percentage of cells
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positive for CD44 and a-tubulin. Intracellular mean CD44 fluorescence was also
determined using at least 4 different fields in each group across three independent
experiments and data are presented as fold change in intracellular CD44 fluorescence
at 3 and 6 hours compared to control.

Impact of anti-CD44 treatment on MSU phagocytosis by human and murine
macrophages and downstream production of interleukin-1 beta (IL-1b) and
interleukin-8 (IL8)
We used the IM7 clone as the anti-CD44 antibody [40]. IM7 is a monoclonal rat antiCD44 antibody (ThermoFisher Scientific) that recognizes the extracellular domain of
all CD44 isoforms in murine and human cells and results in ECD shedding [40, 41].
The mechanism of ECD shedding involves activation of a sheddase enzyme, mediated
by Rho GTPase activation and actin reorganization [41]. IM7 and rat isotype control
(IC) antibodies (Abcam) were used at 2µg/ml in all experiments. MSU phagocytosis
by THP-1 macrophages following a 4-hour incubation ± anti-CD44 or IC antibodies
was determined by analyzing the change in macrophage side scatter as described above.
Murine J774A.1 macrophages (500,000 cells per well; ATCC) were seeded on cover
slips in 6 wells plates and treated with IM7 or IC antibodies for 4 hours followed by
direct determination of cells positive for MSU crystals across all groups was determined
as described above.
In a separate set of experiments, THP-1 macrophages were treated with MSU crystals
(100 μg/mL) for 2, 4, and 6 h. Media were collected at 2, 4, and 6 h, and IL-1b media
concentrations were determined by ELISA.THP-1 macrophages were treated with
MSU crystals ± anti-CD44 or IC antibodies for 6 hours followed by media collection
and cell harvest to perform IL-1b and IL8 gene expression studies as described above
and using the following commercially available primers and probes for IL-1b
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(Hs01555410_m1) and IL8 (Hs00174103_m1) (ThermoFisher Scientific). IL-1b and
IL8 media concentrations were determined by ELISA (Abcam). Soluble CD44 receptor
concentrations following treatments with anti-CD44 or IC antibodies were determined
as described above.
Analysis of NF-kB p65 subunit nuclear levels, NLRP4 inflammasome, pro-IL-1b,
mature IL-1b, and caspase-1 activity following MSU challenge and impact of antiCD44 antibody treatment.
Quantification of NFkB p65 subunit nuclear levels was performed as previously
described [34]. THP-1 macrophages were treated with MSU (100µg/ml) ± anti-CD44
or IC antibodies for 1 hour followed by cell harvest and extraction of nuclear protein.
Nuclear levels of p65 subunit were determined using a DNA binding ELISA assay
(Abcam) and normalized to total nuclear protein content using the micro BCA assay
and expressed as detectable NFkB p65 levels normalized to untreated controls.
Components of the NLRP3 inflammasome were assayed using Western Blotting as
described [ 24]. THP-1 macrophages (3,000,000 cells seeded in a petri dish) were
treated with MSU (100µg/ml) ± anti-CD44 or IC antibodies for 12 hours. Probing
antibodies included anti-NLRP3 (rabbit monoclonal antibody), anti-caspase-1 (pro- and
p10 subunit; rabbit monoclonal antibody), anti-ASC1 (rabbit polyclonal antibody) and
anti-b actin (rabbit polyclonal antibody). All antibodies are commercially available
(Abcam). Probing was performed using 1:1,000 dilution and blots were incubated with
primary antibodies overnight. Following washing with TBS-T, secondary antibody
(HRP-conjugated anti-rabbit goat polyclonal antibody; 1: 2,000 dilution; Abcam) was
added for 1 hour at room temperature followed by washing with TBS-T. Blots were
developed using a chemiluminescent substrate (ThermoFisher Scientific) followed by
imaging using a Bio-Rad imager. Band intensities were determined using Bio-Rad
imager software and data is presented as fold change compared to untreated control.
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Cellular pro-IL-1b and mature IL-1b were determined by ELISA (R&D Systems) and
normalized to total protein level in the cell lysates.
Caspase-1 activity was determined following incubation of THP-1 macrophages with
MSU ± anti-CD44 or IC antibodies as described above. Caspase-1 activity was
determined using Caspase-Glo Assay Kit (Promega, USA) and luminescence intensity
was determined.
Intracellular protein phosphatase-2A (PP2A) activity
PP2A activity was determined using the PP2A activity assay (Promega, USA). THP-1
macrophages were treated with MSU (100µg/ml) ± anti-CD44 or IC antibodies, a PP2A
activator (FTY720; Sigma) (2.5μM), or a PP2A inhibitor (Okadaic acid; Sigma) (5nM)
for 2 hours. To study the role of intracellular PP2A activity in mediating anti-CD44
antibody’s effect, THP-1 macrophages were treated with MSU ± anti-CD44, IC
antibodies or anti-CD44 + okadaic acid for 6 hours followed by determination of IL-1b
gene expression and production as described above.
CD44 regulation of Lipopolysaccharide (LPS) priming of human peripheral blood
mononuclear cells (PBMCs) and macrophages
Primary human PBMCs (500,000 cells per well; ATCC) were incubated with soluble
uric acid (50 mg/dl; Sigma Aldrich) for 24 hours followed by stimulation with LPS (10
ng/ml; Invivogen) for 6 hours ± IM7 or IC antibodies. IL-1b and interleukin-1 receptor
antagonist (IL-1Ra) media concentrations were determined by ELISA (R&D Systems).
THP-1 macrophages (500,000 cells per well) were treated with LPS (10 ng/ml) for 6
hours ± IM7 or IC antibodies followed by determination of IL-1b levels. In a separate
set of experiments, THP-1 macrophages were treated with LPS ± IM7 ± okadaic acid
(5nM) followed by determination of IL-1b levels.
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Murine peritoneal model of acute gout
We employed the MSU peritoneal model of acute gout as previously described [20].
Male mice (12-14 weeks old) that were wildtype (n=8), Cd44-/- (n=8) or Nlrp3-/- (JAX
stock # 021302) (n=6) [41] were injected via the intraperitoneal (i.p.) route with sterile
PBS (200µl) or MSU crystals (2 mg in 200µl) under gas anesthesia. Prior to i.p.
injections, mice abdomens were cleansed with 70% isopropyl alcohol. A total of 3
animals from each genotype were used as untreated controls. At 4 hours following i.p.
injections, animals were euthanized using CO2 and animal abdomens were carefully
opened without violating the integrity of the peritoneal cavity. Peritoneal lavaging was
performed by injecting 4 ml of cold PBS into the peritoneal cavity followed by shaking
for 30-60 seconds and lavage aspiration. Lavage fluids were centrifuged at 450 g for
10 min and supernatants were collected and assayed for IL-1b and interleukin-1
receptor antagonist (IL-1Ra) by ELISA (R&D Systems). Cell pellets were resuspended
in 1 ml PBS and total cell numbers were determined using a hemocytometer.
Live cells were identified by side and forward scatter gating. For flow cytometry, cells
were stained with a combination of anti-mouse Ly6b-FITC and Ly6G-APC to identify
neutrophils [42] or a combination of anti-mouse Cd11b-FITC and Ly6C-APC to
identify monocytes [43].

Antibodies (Abcam) were used at 1:100 dilutions and

incubated for 1 hour at 4oC in the dark. Following staining, cells were washed with
PBS and fixed in PBS containing 2% paraformaldehyde and analyzed using a flow
cytometer. Infiltrating neutrophils were determined by multiplying total cell number
by percentage of cells that were Ly6b+/Ly6G+. Similarly, infiltrating monocytes were
determined by multiplying total cell number by percentage of cells that were
Cd11b+/Ly6C+.
In another set of experiments, male wildtype mice (12-14 weeks old) were randomly
assigned to the following experimental groups: untreated controls (n=4), MSU +
vehicle treated (n=4), MSU + anti-CD44 treated (n=5) or MSU + IC treated (n=3).
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MSU (2 mg in 200µl), vehicle (PBS; 200µl), anti-CD44 (50µg in 200µl) or IC (50µg
in 200µl) injections were performed via the i.p. route as described above. At 4 hours
following injections, peritoneal lavaging and cell phenotypic analyses were conducted
as described above.

Peritoneal lavage IL-1β concentrations were determined by

ELISA.
Statistical analyses
Statistical analyses of gene expression data were performed using ΔCt values (Ct target
gene-Ct GAPDH) for each gene of interest in each experimental group. Continuous
variables were initially evaluated whether they satisfied the requirements for parametric
statistical tests. Statistical significance comparing two groups or multiple groups with
parametric data was assessed by Student’s t test or ANOVA followed by post-hoc
multiple comparisons using Tukey’s post-hoc test. Statistical significance comparing
two groups or multiple groups with nonparametric data was assessed by Rank Sum test
or ANOVA on the ranks. A p value of < 0.05 was considered statistically significant.
Data are presented as scatter plots with mean and standard deviations highlighted. Data
were generated from at least 3 independent experiments with duplicate wells per
treatment.

Results
Latex beads and MSU Crystal phagocytosis, LDH release and downstream IL-1b
expression and production were lower in Cd44-/- BMDMs compared to Cd44+/+
BMDMs and a CD44 antibody blocked crystal uptake by murine macrophages
The absence of CD44 receptor resulted in a significant reduction in BMDM phagocytic
activity against latex beads and MSU crystals. As shown in Figure 3-1A (p<0.01),
Cd44-/- BMDMs exhibited a significantly lower phagocytic activity towards latex beads
compared to Cd44+/+ BMDMs .Similarly, Cd44-/- BMDMs showed a significantly
lower MSU phagocytic response compared to Cd44+/+ BMDMs (fig. 3-1B & C;
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p<0.01). To investigate whether differences in MSU crystal phagocytosis as a function
of CD44 genotype is an artefact of differential macrophage cytotoxicity, we studied
LDH release from BMDMs following MSU exposure. Cd44-/- BMDMs showed a
significantly lower LDH release at 1 and 4 hours compared to Cd44+/+ BMDMs (fig.
3-1D). Expression of IL-1b gene in MSU-stimulated Cd44+/+ and Cd44-/- BMDMs
were higher than unstimulated control BMDMs (fig. 3-1E; p<0.001). However, IL-1b
fold gene expression in Cd44+/+ BMDMs was higher than IL-1b gene expression in
Cd44-/- BMDMs (fig. 3-1E; p<0.05). We observed a biologically relevant mean 38%
reduction in IL-1b expression in Cd44-/- BMDMs, which is attributed to reduced MSU
phagocytosis due to the lack of CD44 receptor expression. Likewise, IL-1b production
was higher in MSU-stimulated Cd44+/+ BMDMs compared to Cd44-/- BMDMs (fig. 31F; p<0.001). While MSU caused a significant increase in detected IL-1b protein from
Cd44+/+ BMDMs (fig. 3-1F; p<0.001), no significant increase in IL-1b was detected in
Cd44-/- BMDMs (fig. 3-1F; p=0.063). LPS had a greater inflammatory response on
Cd44+/+ BMDMs compared to Cd44-/- BMDMs (fig. 3-1F, p<0.001). Using murine
macrophages, anti-CD44 antibody treatment reduced MSU uptake compared to MSU
alone (fig. 3-1 G and 1H, p<0.001) or MSU + IC antibody (fig. 3-1H, p<0.05). In
contrast, IC antibody treatment did not alter MSU uptake by the J774A macrophages
(fig. 3-1H, p>0.05).
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Figure 3-1
Role of CD44 receptor in mediating monosodium urate monohydrate (MSU) crystal phagocytosis and downstream
inflammation in bone marrow derived macrophages (BMDMs) from Cd44+/+ and Cd44-/- mice and impact of
antibody-mediated receptor shedding on MSU phagocytosis by murine macrophages. A. Cd44-/- BMDMs
demonstrated reduced phagocytic activity against FITC-labeled antibody-coated beads compared to Cd44+/+
BMDMs. B. A representative image showing MSU crystal internalization in Cd44+/+ and Cd44-/- BMDMs following
incubation with MSU crystals for 4 hours. Arrows point to cells with internalized MSU crystals. C. Cd44-/-BMDMs
showed reduced MSU phagocytosis. D. Cd44-/-BMDMs exhibited reduced LDH release compared to Cd44+/+
BMDMs. E. Cd44-/- BMDMs had lower IL-1b gene expression in response to MSU. F. Cd44-/-BMDMs had lower
IL-1b production in response to MSU. G. Representative images depicting the impact of anti-CD44 antibody
treatment on MSU phagocytosis by murine J774A.1 macrophages. Arrows point to cells with internalized MSU
crystals. H. Anti-CD44 antibody treatment reduced MSU phagocytosis by murine macrophages. Data from 3-5
independent experiments are presented with mean and S.D. highlighted. *p<0.001; **p<0.01; ***p<0.05; n.s.: nonsignificant. Scale bar = 50µm. Dashed line represents gene expression in untreated controls.
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CD44 expression level was associated with phagocytic activity in THP-1
macrophages and exposure to MSU crystals was associated with enhanced CD44
receptor expression and cytosolic CD44 localization in THP-1 macrophages
Crystals were detected intracellularly in MSU-treated THP-1 macrophages by direct
visualization while MCF-7 cells showed no internalized crystals (fig. 3-2A). Using flow
cytometry, we also detected MSU-positive THP-1 macrophages, while we failed to
detect MSU-positive MCF-7 cells (fig. 3-2B).

Figure 3-2
Comparative phagocytic activities of human THP-1 macrophage and breast cancer cell line (MCF-7) against
monosodium urate monohydrate (MSU) crystals using direct visualization and indirect flow cytometry side-scatter.
A. Representative images showing crystals in MSU- treated THP-1 macrophages (white arrows) while no crystals
were detected in MSU- treated MCF-7 cells. B. MSU phagocytosis was observed in THP-1 macrophage using sidescatter analysis but not in MCF-7 cells. *p<0.001; n.s.: non- significant; Scale bar = 25μm.
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As a result of MSU stimulation, time-dependent CD44 gene expression increased as
evidence by elevated CD44 gene expression at 12 and 24 hours compared to 3 and 6
hours (Fig. 3-3A; p<0.001). Over the same treatment period, cell surface CD44 protein
staining also increased. A representative flow cytometry plot of CD44 receptor cellassociated fluorescence is shown in figure 3-3B. CD44 mean fluorescence intensity in
THP-1 macrophages was higher at 12 and 24 hours compared to 3 and 6 hours (fig. 33C; p<0.001). In addition to surface receptor expression, soluble CD44 receptor levels
increased at 24 hours compared to untreated control (Fig. 3-3D; p<0.001).
Representative images, taken from different fields from the same slide, showing MSU
crystal phagocytosis and CD44 receptor intracellular localization at 3 and 6 hours are
shown in figure 3-3E.

Arrows point to internalized MSU crystals and positive

colocalization of CD44 receptor and a-tubulin at 3 and 6 hours. The percentage of
macrophages showing positive intracellular colocalization of CD44 and a-tubulin was
higher at 3 hours compared to untreated cells (p<0.001) and 6-hour MSU treatment
(p<0.01) (fig. 3-3F). Similarly, intracellular CD44 staining intensity was higher at 3
hours compared to untreated cells (p<0.001) and 6-hour treatment (p<0.01) (fig. 3-3G).
The lack of intracellular CD44 staining and colocalization with a-tubulin in control
untreated THP-1 macrophages is expected as CD44 is normally found on cell surface.
Therefore, the increase in intracellular CD44 staining intensity at 3-hour and 6-hour
MSU treatment is indicative of CD44 receptor internalization. This is supported by the
7.8-fold mean increase in intracellular CD44 staining intensity at 3 hours compared to
control, wherein de-novo CD44 expression increased by ~ 40% over the same treatment
period.
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Figure 3-3
Impact of monosodium urate monohydrate (MSU) crystals on CD44 receptor expression and internalization in
differentiated human THP-1 macrophages. A. CD44 expression exhibited a time-dependent increase following
incubation with MSU crystals. CD44 expression at 12 and 24 hours was higher than expression at 3 and 6 hours.
CD44 expression in MSU-challenged macrophages was higher than controls across all time points. B. A
representative flow cytometry histogram demonstrating elevated surface CD44 receptor protein on THP-1
macrophages following incubation with MSU crystals. C. Semi-quantitative analysis of mean fluorescence intensity
of CD44 receptor following incubation with MSU crystals. Surface CD44 receptor protein levels were higher at 12
and 24 hours compared with 3 and 6 hours. CD44 protein increased following incubation with MSU across all time
points. D. Soluble CD44 receptor concentration increased at 24 hours following incubation with MSU crystals. E.
Representative images of CD44 receptor (green) and a-tubulin (red) colocalization in MSU-treated THP-1
macrophages at 3 and 6 hours following incubation with MSU crystals. Top panel illustrates MSU phagocytosis by
THP-1 macrophages at 3 and 6 hours, acquired from a different field in the same experiment. Arrows point to
internalized MSU crystals at 3 and 6 hours. In the merged panel, arrows point to CD44 receptor and a-tubulin colocalization indicating CD44 receptor internalization. Median colocalization images are presented. F. CD44 and atubulin colocalized intracellularly at 3 and 6 hours following MSU exposure. G. Intracellular CD44 staining intensity
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increased following exposure to MSU crystals. Data from 3 independent experiments are presented with mean and
S.D. highlighted. *p<0.001; **p<0.01; ***p<0.05. Scale bar = 10 μm.

Antibody-mediated CD44 ECD shedding reduced MSU crystal phagocytosis, NFkB p65 nuclear levels, conversion of procaspase-1 to caspase-1 and downstream

IL-1b and IL8 expression mediated by PP2A
We confirmed that anti-CD44 antibody treatment induced CD44 ECD shedding in
THP-1 macrophages. Mean soluble CD44 levels in MSU+anti-CD44 group was higher
than corresponding mean levels in MSU alone or MSU + IC antibody (fig.3-4A;
p<0.001). Antibody-mediated shedding of CD44 ECD significantly reduced MSU
phagocytosis as determined by flow cytometry (fig. 3-4B; p<0.001). The lack of an
effect by IC antibody on MSU phagocytosis (fig. 3-4B) furthers confirms the role of
CD44 in mediating MSU crystal uptake by macrophages.
We initially studied the time-dependent IL-1β expression and secretion following the
incubation of THP-1 macrophages with MSU crystals (100 μg/mL) (fig. 3-4C and 34D). At 6 h, MSU induced a significant increase IL-1β expression and secretion.
Anti-CD44 antibody treatment reduced IL-1β gene expression (fig. 3-4E; p<0.001) and
production (fig. 3-4G; p<0.01) in MSU-stimulated THP-1 macrophages with no effect
by IC antibody treatments. Similarly, anti-CD44 antibody treatment reduced IL8 gene
expression (fig. 3-4F; p<0.001) and production (fig. 3-4H; p<0.001) with no effect by
IC antibody (p>0.05).

42

Figure 3-4
Impact of antibody-mediated CD44 receptor shedding on monosodium urate monohydrate (MSU) crystals
phagocytosis by THP-1 macrophages, expression and production of interleukin-1 beta (IL-1b) and interleukin-8
(IL8). A. Anti-CD44 antibody treatment increased CD44 receptor shedding by macrophages. B. Anti-CD44
antibody treatment reduced MSU phagocytosis by THP-1 macrophages. C. MSU increased IL-1b gene expression
by THP-1 macrophages at 6 h compared to 2 and 4 h. D. MSU increased IL-1b production by THP-1 macrophages
at 6 h compared to 2 and 4 h. E. Anti-CD44 antibody reduced MSU-induced IL-1b expression. F. Anti-CD44
antibody reduced MSU-induced IL8 expression. G. Anti-CD44 antibody reduced IL-1b production. H. Anti-CD44
antibody reduced IL8 production. Data from 3-5 independent experiments are presented with mean and S.D.
highlighted. Dashed line represents gene expression in untreated controls. *p<0.001; **p<0.01; ***p<0.05.
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We investigated the impact of anti-CD44 antibody treatment on procaspase-1
conversion to active caspase-1, caspase-1 activity and assayed pro-IL-1b and mature
IL-1b levels in THP-1 macrophages. Anti-CD44 antibody treatment significantly
reduced conversion of procasapase-1 to active caspase-1 (p<0.001; fig. 3-5A and B).
The p10 caspase-1 subunit/procaspase-1 ratio was reduced with anti-CD44 treatment
compared to MSU alone with no observed effect by IC treatment. To confirm this
observation, we assayed caspase-1 activity levels across different experimental
treatments. While MSU treatment increased caspase-1 activity in THP-1 macrophages
(p<0.001; fig. 3-5C), anti-CD44 treatment significantly reduced caspase-1 activity to
untreated control level (p<0.001). Reduction in procaspase-1 conversion to caspase-1
will reduce conversion of pro-IL-1b to mature IL-1b. Anti-CD44 antibody treatment
reduced intracellular pro-IL-1β (p<0.001; fig. 3-5D) and mature IL-1β (p<0.001; fig.
3-5E). Pro-IL-1b is regulated by NF-kB, and anti-CD44 antibody reduced cellular proIL-1b levels mediated by reducing nuclear NF-kB p65 nuclear levels (p<0.001; fig. 35F).
MSU crystals reduced intracellular PP2A activity in THP-1 macrophages (p<0.001;
Fig. 3-5G).

Anti-CD44 treatment increased intracellular PP2A activity in MSU

stimulated and unstimulated macrophages with no observed effect by IC antibody
(p<0.001).

The magnitude of PP2A activity enhancement by anti-CD44 was

comparable to the positive control treatment. We investigated the role of PP2A in
mediating anti-CD44 treatment effect by co-incubating anti-CD44 with a potent PP2A
inhibitor, followed by assay of IL-1b expression and protein levels. IL-1β expression
in MSU + anti-CD44 + PP2A inhibitor group was higher than MSU + anti-CD44
(p<0.001; fig. 3-5H). Similarly, IL-1β production in MSU + anti-CD44 + PP2A
inhibitor group was higher than MSU + anti-CD44 group (p<0.001; fig. 3-5I). Coincubation with a PP2A inhibitor reversed the effect of anti-CD44 antibody on IL-1β
expression and production, which indicates that the effect of anti-CD44 was mediated
by its PP2A activation effect.
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Figure 3-5
Impact of anti-CD44 antibody treatment on NLRP3 inflammasome activation and nuclear factor kappa B (NFkB)
p65 subunit nuclear translocation in differentiated human THP-1 macrophages following incubation with
monosodium urate monohydrate (MSU) crystals and role of intracellular protein-phosphatase 2A (PP2A) in
mediating anti-CD44’s effect. A. Representative Western Blots of NLRP3 inflammasome components. Anti-CD44
antibody treatment reduced procaspase conversion to active caspase-1. B. Anti-CD44 antibody reduced MSUinduced generation of p10 subunit of active caspase-1 in macrophages. C. Anti-CD44 antibody reduced caspase-1
activity. D. Anti-CD44 antibody reduced intracellular pro-IL-1b levels. E. Anti-CD44 antibody reduced intracellular
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mature IL-1b levels. F. Anti-CD44 antibody reduced NF-kB p65 subunit nuclear levels. G. Anti-CD44 antibody
increased intracellular PP2A activity. H. Co-treatment with anti-CD44 antibody and a PP2A inhibitor increased IL1b expression. I. Co-treatment with anti-CD44 antibody and a PP2A inhibitor increased IL-1b production. Data
from 3 independent experiments are presented with mean and S.D. highlighted. *p<0.001; **p<0.01; ***p<0.05.
The representative Western Blots shown represent two separate experiments. One experiment that included Control,
MSU, MSU+Anti-CD44 and MSU+IC. The other experiment included Control, Anti-CD44 and IC. The different
proteins that we probed for were run on separate gels using the same experimental samples.

Targeting CD44 receptor reduced LPS priming of PBMCs and macrophages
mediated by PP2A
A combination of soluble uric acid and LPS produced higher IL-1β concentrations in
primary human PBMCs compared to no treatment (fig. 3-6A; p<0.001). IL-1β levels
were lower in UA + LPS + IM7 antibody compared to UA + LPS alone or UA + LPS
+ IC antibody (p<0.001 for both comparisons). Soluble uric acid and LPS reduced IL1Ra production by PBMCs compared to untreated controls (fig. 3-6B; p<0.01). IL-1Ra
levels were higher in UA + LPS + IM7 group compared to UA + LPS and UA + LPS
+ IC groups (p<0.01 for both comparisons). LPS treatment increased IL-1β production
in THP-1 macrophages (fig. 3-6C; p<0.001). IM7 antibody treatment reduced IL-1β
production in LPS-stimulated THP-1 macrophages. In contrast, IC antibody treatment
did not alter IL-1β production. Co-incubation with a PP2A inhibitor reversed the effect
of IM7 antibody on IL-1β production in THP-1 macrophages. IL-1β production in LPS
+ IM7 + PP2A inhibitor group was higher than LPS + IM7 group (fig. 3-6D; p<0.01).
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Figure 3-6
Impact of anti-CD44 receptor antibody on lipopolysaccharide (LPS) priming of primary human peripheral blood
mononuclear cells (PBMCs) and macrophages. A. IM7 antibody reduced IL-1β production in UA + LPS stimulated
PBMCs. B. IM7 antibody increased IL-1Ra production in UA + LPS stimulated PBMCs. C. IM7 antibody reduced
IL-1β production in LPS stimulated THP-1 macrophages. D. Co-treatment with IM7 antibody and a PP2A inhibitor
increased IL-1b production. Data from 3 independent experiments are presented with mean and S.D. highlighted.
*p<0.001; **p<0.01; ***p<0.05.

Intraperitoneal MSU did not trigger an inflammatory response in Cd44-/- mice
and anti-CD44 antibody treatment reduced peritoneal inflammation model in
wildtype animals.
Intraperitoneal MSU administration resulted in a significant increase in recovered total
cell count in wildtype mice compared to PBS-administered or untreated control
counterparts (p<0.01 for both comparisons; fig. 3-7A). MSU administration did not
change total cell numbers recovered in peritoneal lavage in Cd44-/- or Nlrp3-/- mice
compared to PBS alone (p>0.05). Total cell numbers in peritoneal lavage from MSUadministered wildtype mice were higher than total cells in Cd44-/- and Nlrp3-/- mice
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(p<0.001 for both comparisons). MSU administration increased infiltrated neutrophils
in wildtype mice compared to PBS alone (p<0.01; fig. 3-7B). In contrast, MSU
administration did not increase infiltrated neutrophils in Cd44-/- or Nlrp3-/- mice
(p>0.05 for both comparisons). The number of infiltrated neutrophils was higher in
MSU-administered wildtype mice compared to MSU-administered Cd44-/- and Nlrp3/- mice (p<0.01 for both comparisons). A similar genotype-dependent trend was
observed for infiltrated inflammatory monocytes following MSU administration (fig.
3-7C). A significant increase in infiltrated monocytes following MSU administration
was observed in wildtype mice (p<0.001) while no change was observed in Cd44-/- or
Nlrp3-/- mice (p>0.05). These findings indicate that both Cd44-/- and Nlrp3-/- genotypes
showed a blunted inflammatory response towards MSU, highlighted by the lack of
neutrophil and monocyte recruitment to the peritoneum.
Lavage IL-1β levels in MSU-administered wildtype mice were higher than
corresponding levels in PBS-administered mice (p<0.001; fig. 3-7D). Lavage IL-1β
levels were also higher in MSU-administered wildtype mice compared to MSUadministered Cd44-/- (p<0.01) or Nlrp3-/- (p<0.001) mice. We detected IL-1Ra in
lavage fluids from control wildtype mice (fig. 3-7E). Intraperitoneal MSU and PBS
administration increased lavage IL-1Ra levels and MSU resulted in higher IL-1Ra
levels compared to PBS (p<0.001). Similarly, MSU administration resulted in higher
IL-1Ra lavage levels in Cd44-/- and Nlrp3-/- mice compared to PBS administration
(p<0.001 for both comparisons). IL-1Ra levels in MSU-administered wildtype mice
were lower than corresponding levels in Cd44-/- mice (p<0.001) or Nlrp3-/-mice
(p<0.01). The IL-1Ra/IL-1β ratios in MSU-administered Nlrp3-/- and Cd44-/- mice
were higher than corresponding Il-1Ra/IL-1β ratio in MSU-administered wildtype mice
(p<0.001 for both comparisons; fig. 3-7F). IL-1Ra is the endogenous antagonist to IL1b, and functions to regulate inflammatory response. The higher levels of IL-1Ra in
Cd44-/- and Nlrp3-/-mice, following MSU challenge, contributes to the lack of
inflammatory response in both genotypes.
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Figure 3-7
Impact of intraperitoneal administration of monosodium urate monohydrate (MSU) crystals on inflammatory cell
infiltration and production of interleukin-1 beta (IL-1β) and interleukin-1 receptor antagonist (IL-1Ra) in wildtype,
Cd44-/- and Nlrp3-/- mice. A. MSU administration in Cd44-/- mice did not result in an increase in overall
inflammatory cell infiltration. B. MSU administration in Cd44-/- mice did not result in increased neutrophil
infiltration. C. MSU administration in Cd44-/- mice did not result in increased Ly6Chi monocyte infiltration. D.
MSU administration in Cd44-/- mice did not result in increased peritoneal IL-1β levels. E. MSU administration in
Cd44-/- mice increased peritoneal IL-1Ra production. F. Lavage IL-1Ra/IL-1β ratio was higher in Cd44-/mice.*p<0.001; **p<0.01; ***p<0.05.

Anti-CD44 antibody treatment reduced the number of total cells recovered in peritoneal
lavages compared to vehicle treatment (p<0.01; fig. 3-8A). Anti-CD44 antibody
treatment reduced the number of infiltrated neutrophils compared to vehicle and IC
treatment groups (p<0.01; p<0.001; fig. 3-8B).
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Similarly, anti-CD44 antibody

treatment reduced the number of infiltrated inflammatory monocytes compared to
vehicle and IC treatment groups (p<0.001 for both comparisons; fig. 3-8C). Lavage
IL-1 β levels in MSU + anti-CD44 antibody group were lower than corresponding
levels in MSU + vehicle and MSU + IC treatments (p<0.01 for both comparisons; fig.
3-8D).

Figure 3-8
Impact of anti-CD44 antibody treatment on inflammatory cell infiltration and production of interleukin-1 beta (IL1β) in murine peritoneal monosodium urate monohydrate (MSU) crystal inflammation model. MSU crystals (2mg
in 200μl PBS), vehicle (Veh.; 200μl PBS), anti-CD44 and isotype control (IC) antibodies (50μg in 200 μl PBS) were
administered via the intraperitoneal route.

A. Anti-CD44 antibody treatment reduced total cell recovered in

peritoneal lavage following MSU administration. B. Anti-CD44 antibody treatment reduced neutrophil infiltration
in MSU peritoneal inflammation model. C. Anti-CD44 antibody treatment reduced Ly6Chi monocyte infiltration in
MSU peritoneal inflammation model. D. Anti-CD44 antibody treatment reduced lavage IL-1β levels compared to
vehicle or IC antibody treatments. *p<0.001; **p<0.01; ***p<0.05.
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Discussion
In this study, we investigated the role of CD44 receptor in mediating urate crystal
phagocytosis by macrophages from different origins and examined the associated
signaling pathway triggered by shedding of the extracellular domain of the receptor.
Urate crystals were uptaken by CD44-competent macrophages to a greater extent
compared to macrophages that lacked CD44. The reduced uptake of crystals by CD44
deficient macrophages resulted in reduced macrophage necrosis and LDH release.
Furthermore, the reduced crystal phagocytosis was associated with attenuated induction
of IL-1β expression and production. Interestingly, the magnitude of reduction in crystal
phagocytic uptake by murine macrophages due to CD44 deficiency paralleled the
magnitude of reduction in IL-1β expression and was comparable to the previously
reported inflammatory response of TLR2 and TLR4 deficient macrophages [22]. The
involvement of CD44 receptor in the uptake of urate crystals by murine macrophages
was further confirmed by the observed reduction in crystal internalization as a result of
antibody-mediated receptor shedding. The surface expression level of CD44 receptor
may play a role in controlling the phagocytic behavior of different cell types. CD44
expression was higher in human macrophages compared to a breast carcinoma cell line,
and that differential expression was associated with crystal phagocytosis.

The

observation that CD44 is a phagocytic receptor [44] is further confirmed by our finding
that CD44 deficient macrophages had a lower phagocytic activity towards latex beads
compared to CD44 competent macrophages.

In human macrophages, CD44

translocated to the cytosol in response to urate crystals. Receptor translocation occurred
rapidly, coincided with crystal uptake and was detectable up to 6 hours following urate
crystal exposure. Antibody-mediated CD44 extracellular domain shedding resulted in
a significant reduction in crystal uptake by human macrophages and downstream
reduction in proinflammatory and chemokine expression and production.

The

reduction in IL8 expression and production is particularly relevant due to the important
role of the IL8/CXCR-2 axis in mediating neutrophil infiltration in models of urate
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crystal inflammation [45-47]. The observed effect of the antibody was specific to the
CD44 receptor as no effect on phagocytosis or expression of cytokines was observed
with the isotype control antibody. Our results suggest that the extracellular domain of
CD44 receptor recognizes and binds naked urate crystals resulting in internalization of
the crystal-receptor complex. The cleavage of the ECD may have reduced the number
of available binding sites for the urate crystals, which translated into reduced crystal
phagocytosis. While urate crystals were reported to non-specifically bind more than 20
plasma proteins [22, 48, 49], their interaction with CD44 appears to be biologically
significant in the context of how macrophages respond to urate crystal danger signals.
IL-1β is a potent multifunctional proinflammatory cytokine that is pivotal in acute gout
and clinically available IL-1 inhibitors, e.g. recombinant human IL-1Ra, were shown
to be effective in relieving signs and symptoms of acute gout flares [50]. Unlike other
proinflammatory cytokines e.g. TNF-α and IL-6, IL-1β is initially produced as a
biologically inactive precursor, pro-IL-1β as a result of priming of monocytes and/or
macrophages [21]. Pro-IL-1β requires further intracellular processing by caspase-1 for
the generation of mature IL-1β [21]. Priming of macrophages can occur as a result of
exposure to TLR ligands including MSU crystals [21]. In our study, exposure to MSU
crystals resulted in priming and activation of murine and human macrophages. MSU
crystals enhanced the nuclear translocation of NF-kB p65 subunit, increased pro-IL-1β
production and enhanced the conversion of procaspase to activated caspase-1 resulting
in increased intracellular caspase-1 activity and secreted mature IL-1β levels. CD44
appears to play a role in regulating macrophage priming by TLR2 and TLR4 agonists
as evidenced by our prior [34] and current finding that CD44-deficient macrophages
were not as responsive towards Pam3CSK4 (A TLR2 ligand) or LPS (a TLR4 ligand)
stimulation as CD44 competent macrophages. Antibody-mediated CD44 extracellular
domain shedding blocked the priming signal by MSU crystals mediated by reduced NFkB activation, resulting in reduced IL-1β gene expression and pro-IL-1β production.
Related to NLRP3 inflammasome, anti-CD44 antibody reduced procaspase conversion
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to caspase-1 which reduced mature IL-1β generation. The inhibitory effect of antiCD44 antibody on NLRP3 inflammasome activity was a downstream effector of its
blocking MSU uptake by macrophages. These effects were specific for targeting the
CD44 receptor as the isotype control antibody showed no effect on NLRP3
inflammasome activation.
The role of CD44 in regulating macrophage priming by MSU crystals is independent
of its role in mediating MSU phagocytic uptake. MSU crystals enhanced CD44 gene
expression and production, consistent with the upregulation of CD44 in the setting of
inflammation and in response to innate immune signals [34]. CD44 receptor is coupled
to multiple signaling pathways including non-receptor Src tyrosine kinases, activators
of small Rho GTPases and PP2A [34, 51-53]. The type of signaling pathway coupled
to CD44 is cell specific and depends on the ligand that engages the receptor [54]. In
addition, the cytoplasmic tail of the receptor can be cleaved off by γ-secretase where it
translocates to the nucleus and acts as a transcriptional regulator [54]. PP2A is a
member of the intracellular serine/threonine phosphatases and plays a counterregulatory role in deactivating phosphorylation-dependent pathways involved in innate
immune macrophage activation [55, 56]. Gene deletion of PP2A was shown to magnify
the inflammatory response of peritoneal macrophages in response to LPS [56] and we
have reported that an anti-CD44 antibody reduced TLR2 ligand induced inflammation
in macrophages mediated by intracellular PP2A [34]. Consistent with the role of MSU
crystals as an innate immune danger signal, MSU reduced intracellular PP2A activity
while an anti-CD44 antibody enhanced basal PP2A activity in cells that were treated
with the antibody alone or a combination of the crystals and the antibody. The increase
in intracellular PP2A activity as a result of CD44 extracellular domain cleavage was
similar to the enhancement in PP2A activity by the PP2A-activating drug FTY720 [57].
The anti-inflammatory activity of anti-CD44 was mediated by upregulated PP2A
activity as inhibition of intracellular PP2A reversed the effect of the antibody and
exacerbated the inflammatory response of macrophages towards MSU crystals. A
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pharmacological activity of IM7 was also observed in a model of LPS-induced priming
of human macrophages where IM7 reduced IL-1β production in a PP2A-dependent
manner. In addition, stimulation of PBMCs from health volunteers by LPS and soluble
uric acid resulted in increased expression and secretion of mature IL-1β and decreased
expression and secretion of IL-1Ra resulting in a lower IL-1Ra/IL-1β ratio. IM7
antibody-mediated shedding of CD44 extracellular domain corrected the IL-1Ra/IL-1β
ratio and conferred an anti-inflammatory effect on PBMCs. As TLR agonists play a
significant role in enhancing systemic inflammation in models of acute gout and in
patients with gout, CD44 targeting may prove beneficial in reducing IL-1β secretion
and restoring the anti-inflammatory IL-1Ra levels in sera from patients with acute gout
[63, 64].
Neutrophil and monocyte transendothelial recruitment and activation are critical to the
onset of inflammation in acute gout [5, 21]. Crystal-induced neutrophil influx was
shown to be CXCR2-dependent and relied on NLRP3 inflammasome activation in-vivo
[58]. The interaction between neutrophils and MSU crystals results in phagocytosis of
MSU by neutrophils and the secretion of proinflammatory cytokines and chemokines
that recruit more neutrophils to the site of inflammation [59, 60]. In addition, apoptosis
of neutrophils by the phagocytosed crystals results in formation of neutrophil
extracellular traps (NETs), which continue to release proinflammatory cytokines [60].
As inflammation progresses and in the presence of high density of neutrophils,
aggregation of NETs take place and these newly formed aggregated NETs exert an antiinflammatory effect due to their ability to degrade pro-inflammatory cytokines e.g. IL1b and IL-6 [59, 60]. In our peritoneal gout model, we showed enhanced recruitment
of neutrophils and monocytes following peritoneal MSU challenge, similar to what was
previously reported [20, 22]. Recruitment of neutrophils and monocytes was associated
with increased IL-1b secretion in the peritoneum. In contrast to CD44-competent
animals, CD44 deficient mice exhibited a blunted neutrophil and monocyte recruitment
with approximately 60% reduction in number of infiltrated neutrophils and monocytes.
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Common between CD44 and NLRP3 deficient mice are the lack of inflammatory cell
infiltration, blunted generation of IL-1b and higher IL-Ra levels.

IL-1Ra is an

important modulator of inflammation and the higher IL-1Ra levels in CD44 deficient
mice contributes to the resistance of this phenotype towards crystal induced
inflammation. The mechanism by which the lack of CD44 drives higher IL-1Ra
expression remains unclear. IL-1Ra and IL-1b were shown to be regulated in opposite
directions by the phosphatidylinositide-3 kinase (PI3K) pathway in monocytes and
macrophages [61]. Furthermore, peroxisome-proliferator-activated receptor gamma
(PPARg) ligands upregulated IL-1Ra expression in THP-1 macrophages [62]. Since
CD44 regulates different signaling pathways including PI3K/AKT pathway [30], the
enhanced expression of IL-1Ra in CD44 deficient macrophages might be related to
increased activation of the PI3K pathway in the absence of CD44. Targeting CD44 in
wildtype animals had a biologically-significant anti-inflammatory effect and
recapitulated the CD44 deficient phenotype, evidenced by reduced neutrophils and
monocyte recruitment and IL-1b generation. Taken together, our in-vivo findings
strongly support that CD44 is essential to the pathogenesis of gout, and
pharmacological manipulation of its role is efficacious in models of acute urate crystal
induced inflammation.

Conclusion
We investigated the role of CD44 in mediating MSU crystal induced inflammation invitro and in-vivo. CD44 mediated the phagocytic uptake of MSU with intracellular
translocation of the receptor as a result of exposure to MSU crystals. Antibodymediated CD44 extracellular domain shedding reduced MSU phagocytosis in murine
and human macrophages. CD44 extracellular domain shedding also reduced MSU
mediated NF-kB nuclear translocation and pro-IL-1b production.

Conversion of

procaspase to caspase-1, caspase-1 activity and secretion of mature IL-1b was also
inhibited by antibody-mediated CD44 extracellular domain shedding. Shedding of the
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extracellular domain also reduced LPS mediated priming of PBMCs macrophages with
a reduction in -IL-1b production. CD44 deficiency protected mice from inflammation
and recruitment of neutrophils and monocytes in a model of acute gout. Anti-CD44
treatment abrogated the recruitment of neutrophils and monocytes and reduced
inflammation in the same model. CD44 receptor plays a significant role in pathogenesis
of MSU inflammation and pharmacological strategies that target this receptor present a
novel approach to treat acute gout.
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Chapter 4: Design and Biological Evaluation of Colchicine-CD44Targeted Peptide Conjugate in an In Vitro Model of Crystal Induced
Inflammation
Abstract
Gout is an inflammatory arthritis due to the joint deposition of monosodium urate
(MSU) crystals. Phagocytosis of MSU crystals by tissue macrophages results in the
generation of reactive oxygen species (ROS) and production of inflammatory cytokines
and chemokines. Colchicine use in gout is limited by severe toxicity. CD44 is a
transmembrane glycoprotein that is highly expressed in tissue macrophages and may
be involved in gout pathogenesis. The P6 peptide is a 20-amino acid residue peptide
that binds to CD44. We hypothesized that the conjugation of colchicine to the P6
peptide will reduce its off-target cytotoxicity while preserving its anti-inflammatory
effect. A modified version of P6 peptide and colchicine-P6 peptide conjugate were
synthesized using Fmoc/tBu solid-phase and solution-phase chemistry, respectively. A
glutaryl amide was used as a linker. The P6 peptide was evaluated for its binding to
CD44, association, and internalization by macrophages. Cytotoxic effects of P6
peptide, colchicine, and colchicine-P6 peptide on macrophages were compared and the
inhibition of ROS generation and interleukin-8 (IL-8) secretion in MSU-stimulated
macrophages treated with P6 peptide, colchicine, or colchicine-P6 peptide was studied.
We confirmed that the P6 peptide binds to CD44 and its association and internalization
by macrophages were CD44-dependent. Colchicine (1, 10, and 25 μM) demonstrated a
significant cytotoxic effect on macrophages while the P6 peptide and colchicine-P6
peptide conjugate (1, 10 and 25 μM) did not alter the viability of the macrophages. The
P6 peptide (10 and 25 μM) reduced ROS generation and IL-8 secretion mediated by a
reduction in MSU phagocytosis by macrophages. The colchicine-P6 peptide
significantly reduced ROS generation and IL-8 secretion compared to the P6 peptide
alone at 1 and 10 μM concentrations. Conjugation of colchicine to the P6 peptide
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reduced the cytotoxic effect of colchicine while preserving its anti-inflammatory
activity.

Introduction
Gout is a prevalent inflammatory arthritis due to the precipitation of serum uric acid
into crystallized deposits of monosodium urate (MSU) crystals in and around the joint
[1–3]. On a worldwide level, it is estimated that between 1 and 3% of males and
females, respectively, between the ages of 40 and 60 years old suffer from gout [4].
Gout flares are characterized by acute episodes of intense pain, severe inflammation,
and joint swelling, with the knee and metatarsophalangeal joints most frequently
affected [1,3]. Management of acute gout flares remains suboptimal and
hospitalizations due to poorly controlled flares have significantly increased over the
past two decades [5–8]. Treatment modalities of acute gout flares include the use of
nonsteroidal anti-inflammatory drugs (NSAIDs), selective cycloxygenase-2 (COX2)
enzyme inhibitors, colchicine, and corticosteroids [9,10]. However, the use of these
agents is not without harm, given the comorbidities seen in older patients with gout
[11–13].

The normal synovium contains two types of intimal cells: type A macrophages and type
B synovial fibroblasts [14]. During an acute episode of gouty arthritis, deposition of
MSU crystals in joints stimulates resident macrophages to produce the inflammatory
cytokine interleukin-1 beta (IL-1β) and inflammatory chemokines, interleukin-8 (IL8), and monocyte chemoattractant protein-1 (MCP-1) [15,16]. The secretion of IL-8
results in the recruitment of inflammatory cells (e.g., neutrophils and monocytes) to the
affected joints [16–18]. This inflammatory cascade is mediated by phagocytosis of
MSU crystals by joint resident macrophages [19,20]. The mechanism of phagocytosis
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is not entirely understood and the toll-like pattern recognition family of receptors
(TLRs) may play a role in facilitating crystal phagocytosis [21,22]. Subsequent to MSU
crystal phagocytosis, reactive oxygen species (ROS) are generated through the
activation of NADPH oxidase and downstream activation of NLRP3 inflammasome
and nuclear factor kappa-b (NF-κB), resulting in the expression and production of IL1β and IL-8 [23–25].
The cluster determinant-44 (CD44) receptor is a single pass transmembrane
glycoprotein that has various functions in cell division, migration, adhesion, and
signaling [26]. CD44 expression level in the synovium may be linked to the
inflammatory status of the joint with increased expression of certain isoforms over the
course of experimental arthritis and in patients with advanced osteoarthritis (OA) [27–
29]. The CD44 receptor may also fulfill a phagocytic function in immune cells [30]. A
number of endogenous ligands to CD44 have been identified including high molecular
weight hyaluronic acid (HA) and the glycoprotein, proteoglycan-4 (PRG4), two major
components of joint synovial fluid (SF) [31]. Binding of HA and PRG4 to CD44 on the
surface of macrophages was shown to result in ligand internalization [32,33].
Furthermore, we have previously shown that recombinant human PRG4 inhibits MSU
phagocytosis by macrophages in a mechanism that may involve CD44 and/or TLR
receptor interactions [33]. The utility of CD44 as a targeting receptor on macrophages
was also reported by utilizing HA-coated nanoparticles to repolarize inflammatory
macrophages to an anti-inflammatory phenotype [34,35].
Colchicine is a natural alkaloid that is used in the management of acute gout flares as
well as prophylaxis against acute gout attacks within six months of initiating chronic
urate-lowering therapy [36]. In addition to its use in gout, colchicine has also shown
clinical efficacy in reducing pain and inflammation in symptomatic OA, treatment of
inflammation in crystal-induced chondrosis due to deposition of calcium
pyrophosphate crystals, and may also have a clinical benefit in lowering cardiovascular
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risk in patients with coronary artery disease [36,37]. Due to its ability to interfere with
microtubule assembly, colchicine can control numerous cell function including
cytokine and chemokine secretion and inflammatory cell migration and proliferation
[36]. This microtubule disrupting effect was also shown to block cancer cells in the
G2/M phase, thus its cytotoxic effect may prove useful for cancer treatment [38]. The
therapeutic effect of colchicine on macrophages in the context of MSU induced
inflammation was shown to lie upstream of microtubule disruption via inhibition of
ROS generation [39]. Due to its off-target cytotoxicity, oral colchicine use is limited by
its gastrointestinal toxicity and drug–drug interactions, particularly in patients with
renal and hepatic impairments resulting in toxic outcomes (e.g., myopathy and liver
damage) [36,37]. In addition, fatalities have been reported due to both accidental and
therapeutic colchicine poisoning [40].
Localized drug delivery into the joint is one potential approach to enhance the joint
residence time of injected therapeutics and reduce systemic exposure of administered
therapeutics. The joint half-life estimates of small molecules and recombinant proteins
following intra-articular administration is in the order of hours due to rapid systemic
clearance [41,42]. Encapsulation of small molecules and proteins in microspheres
offers the advantage of extending their joint residence time and reducing systemic
exposure [43,44]. Given the complexity of formulating microsphere delivery systems,
peptide-drug conjugates (PDC) may offer an outstanding alternative approach to deliver
small molecules selectively to cells or specific targets, thereby enhancing their efficacy
and reducing off-target interactions. PDCs represent an important class of prodrugs that
are formed through covalent binding of a specific peptide sequence to a drug via a
cleavable linker [45]. Given its importance in inflammatory joint disease, CD44
receptor targeting may offer a unique opportunity to deliver intra-articular therapeutics
for

the

treatment

of

joint

inflammatory

diseases.

The

P6

peptide,

FDAIAEIGNQLYLFKDGKYW, is a novel CD44-binding peptide that was identified
from studying the interaction of pro matrix metalloproteinase-9 (pro-MMP-9) with
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CD44 as it relates to the proliferation of chronic lymphocytic leukemia (CLL) cells
[46]. The P6 peptide was shown to effectively prevent pro-MMP-9 CD44-dependent
binding to CLL cells [46].
The overall objective of this study was to evaluate the feasibility of conjugating the P6
peptide to N-deacetylcolchicine via a hydrolyzable linker and study the efficacy and
safety of the colchicine-P6 peptide conjugate in an in vitro model of MSU stimulated
macrophages. We hypothesized that conjugation of colchicine to the P6 peptide will
modify colchicine’s intracellular distribution, thereby reducing its cytotoxic effect
while preserving its anti-inflammatory efficacy. We assessed the anti-inflammatory
efficacy using a combination of IL-8 secretion and ROS generation. We initially studied
CD44 expression in macrophages and characterized the role of CD44 in mediating
MSU crystal uptake by macrophages. We also evaluated the affinity of P6 binding
toward the CD44 receptor using HA as a comparator. We studied the association and
internalization of fluorescently-labeled P6 peptide in human THP-1 macrophages.
Subsequently, we studied the impact of P6 peptide, colchicine, and colchicine-P6
peptide treatments on MSU phagocytosis by macrophages, macrophage cell viability,
production of IL-8, and ROS generation. Finally, we evaluated the stability of the P6
peptide in SF aspirates from donors with no history of degenerative joint disease.

Materials and Methods
Materials
N-Deacetylcolchicine was purchased from DSK Biopharma, Inc. (Morrisville, NC,
USA). All amino acids and resins were purchased from AAPPTEC peptides. All other
chemicals and reagents were purchased from Sigma-Aldrich. The chemical structures
of final products were confirmed by high-resolution MALDI-TOF (GT 0264) from
Bruker Inc. and Bruker Impact IITM UHR-QqTOF (Ultra-High Resolution Qq-TimeOf-Flight) mass spectrometry. Final compounds were purified by a reversed-phase
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HPLC from Shimadzu (LC-20AP) using a gradient system of acetonitrile and water and
a reversed-phase preparative column (XBridge BEH130 Prep C18, Waters, Inc.,
Milford, MA, USA). Phorbol 12-myristate-13-acetate (PMA), soluble uric acid, highbinding microtiter plates (Corning), phosphate buffered saline (PBS), bovine serum
albumin (BSA), fetal bovine serum (FBS), and Tween 20 were purchased from Sigma
Aldrich (St. Louis, MO, USA). The CD44-IgFc fusion protein, HA, recombinant
human IL-1β, IL-8 ELISA, and murine colony stimulating factor (M-CSF) was
purchased from R&D Systems (Minneapolis, MN, USA). Anti-human IgG Fc-HRP,
DyLight 488 goat anti-mouse IgG, anti-CD44 antibody, anti-α-Tubulin antibody,
fluoroshield-mounting medium with DAPI, Cell Counting Kit-8 assay, and ROS assays
were purchased from Abcam (Cambridge, MA, USA). Human THP-1 monocytes and
RPMI-1640 media were purchased from American Type Culture Collection (ATCC)
(Manassas, VA, USA). Pyrogen-free MSU crystals were obtained from Invivogen (San
Diego, CA, USA). Penicillin and Streptomycin cocktail and Turbo TMB-ELISA
substrate were obtained from ThermoFisher Scientific (Waltham, MA, USA). Normal
SF aspirates were obtained from Articular Engineering (Northbrook, IL, USA) from
three donors with no history of arthritis within 24 h of death, collected with partner site
Institutional Review Board approval with informed consent from the nearest relative.
Cd44+/+ and Cd44−/− mice were obtained from Jackson Labs (Bar Harbor, ME, USA).
Methods
Synthesis of P6 Peptide
Fmoc Rink amide resin (0.57 mmol/g, 0.52 g) was swelled in DMF for 15–30 min under
dry nitrogen. The solvent (DMF) was filtered off after agitation. Piperidine in DMF (10
mL, 20% v/v) was used to remove the Fmoc protecting group. Then, the first Fmoc
protected amino acid (Fmoc-Phe-OH) (4 equiv.) was coupled to the N-terminal of the
resin

using

hexafluorophosphate,

N,N,N′,N′-Tetramethyl-O-(1H-benzotriazol-1-yl)uranium
O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium
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hexafluorophosphate (HBTU) (4 equiv.) and N, N-Diisopropylethylamine (DIPEA) (4
equiv.) in DMF under dry nitrogen for 1.5 h. Then, the reaction solution was filtered
out after completion of the coupling. The resin was washed off by DMF (10 mL, 3 × 2
min.). Fmoc deprotection was done by adding piperidine in DMF (20% v/v, 10 mL, 3
× 10 min). The reaction solution was filtered out and washed again with DMF. The
subsequent Fmoc-protected amino acids were coupled to the peptide template until the
last amino acid (Fmoc-Trp(Boc)-OH) was coupled. The final Fmoc deprotection was
carried out to make a free N-terminal for the conjugation of colchicine. Cleavage
cocktail containing TFA, thioanisole, EDT and anisole (90:5:3:2 v/v/v/v, respectively,
6 mL) was used to cleave the resin and all side chain-protecting groups form the peptide
to check the final sequence. The mixture was stirred at room temperature for 4 h. Then,
the crude conjugate was precipitated using cold diethyl ether and centrifuged at 10 G
for 10 min. The precipitant was dissolved in water containing 0.1% TFA and
acetonitrile containing 0.1% TFA in an equal amount (1:1 v/v). After completion of the
synthesis of the 20 amino acid sequence of the P6 peptide, the linear peptide was
confirmed by MALDI analysis (m/z): C115H165N26O30 calculated for M + H.
2390.2185, found 2389.9299 [M + H]+.
Synthesis of Colchicine-Glutaryl Amide Conjugate
Coupling of N-deacetylcolchicine (35 mg, 0.098 mmol) with glutaric anhydride (11.97
mg, 0.105 mmol) was carried out by solution-phase chemistry in the presence of
anhydrous tetrahydrofuran (THF, 10 mL), 4-dimethylaminopyridine (DMAP, 8.5 mg,
0.07 mmol), and triethylamine (TEA, 31.5 μL, 0.23 mmol) as a base. The reaction
mixture was stirred under nitrogen for 4 h. The solvent (THF) was removed by a
rotatory evaporator under reduced pressure and was then dissolved using DCM. Hexane
was used to crystallize the product (30 mg, 64%). The compound was used in
conjugation with resin-attached P6 peptide to afford the desired conjugate with the P6
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peptide. Q-TOF analysis (m/z): C25H30NO8 Calculated, 472.1971 for M + H; Found
472.2045 [M + H]+, 494.1869 [M + Na]+, 510.1610 [M + K]+).
Synthesis of Colchicine-P6 Peptide Conjugate
The peptide-attached resin (230 mg) was used in the coupling with the colchicineglutaryl amide conjugate (30 mg, 0.075 mmol) synthesized by solution-phase
chemistry.

Anhydrous

DMF

(10

mL),

PyBOP

(benzotriazol-1-yl-

oxytripyrrolidinophosphonium hexafluorophosphate (58.5 mg, 0.11 mmol)), 1hydroxybenzotriazole hydrate (HOBt, 30.3 mg, 0.22 mmol), and N, Ndiisopropylethylamine (DIPEA, 80 μL, 0.075 mmol) were added to the reaction mixture
of the peptide-attached resin and colchicine-glutaryl amide conjugate in 1 mL
anhydrous DMF. This reaction mixture was shaken on a rotator overnight. After the
formation of the conjugate was confirmed by MALDI analysis, the crude conjugate was
washed for 2 h using DMF and DCM. The cleavage cocktail containing TFA,
thioanisole, EDT and anisole (90:5:3:2 v/v/v/v, respectively, 6 mL) was used to cleave
the resin and all side chain-protecting groups form the conjugate. The mixture was
stirred at room temperature for 4 h. Then, the crude conjugate was precipitated using
cold diethyl ether and centrifuged at 10 G for 10 min. The precipitant was dissolved in
water containing 0.1% TFA and acetonitrile containing 0.1% TFA in an equal amount
(1:1 v/v). After purification via reversed-phase HPLC and lyophilization (3 mg), the
structure of the conjugate was confirmed by high-resolution MALDI-TOF analysis
(m/z): C140H192N27O37 Calculated, 2843.3972 for M + H, found 2843.8766 [M +
H]+.
Synthesis of Fluorescein-Labeled P6 Peptide
Protected P6 peptide-attached resin (170 mg) was used in the coupling with 5(6)carboxyfluorescein diisobutyrate on a solid support. Anhydrous DMF (10 mL), PyBOP
(39 mg, 0.075 mmol), HOBt (20 mg, 0.15 mmol), and DIPEA (40 μL, 0.23 mmol) in 1
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mL anhydrous DMF was added to the reaction mixture of crude protected peptideattached resin and 5(6)-carboxyfluorescein diisobutyrate (38.5 mg, 0.072 mmol). This
reaction was shaken on a rotator overnight. After the formation of the compound was
confirmed by MALDI analysis, the resin was washed for 2 h using DMF and DCM.
The cleavage cocktail containing TFA, thioanisole, EDT, and anisole (90:5:3:2 v/v/v/v,
respectively, 5 mL) was used to cleave the resin and all side-chain protecting groups
from the compound. The mixture was stirred at room temperature for 4 h. Then, the
crude was precipitated using cold diethyl ether and centrifuged at 10 G for 10 min. The
precipitant was dissolved in water containing 0.1% TFA and acetonitrile containing 0.1
TFA in an equal amount (1:1 v/v) and was purified by reversed-phase HPLC. MALDITOF analysis (m/z): C137H179N26O35 Calculated. 2750.0860 for M + H, found
2749.6489 [M + H]+.
Differentiation of THP-1 Macrophages and CD44 Expression under Conditions of
Inflammation, Isolation of BMDMs from Cd44+/+ and Cd44−/− Animals and
Impact of HA Treatment on MSU Phagocytosis by THP-1 Macrophages
THP-1 monocytes were cultured in RPMI 1640 medium supplemented with 10% heatinactivated FBS, 10 mM HEPES, 2 mM glutamine, 100 U/I penicillin, and 100 μg/mL
streptomycin and maintained at 37 °C and 5% CO2. THP-1 monocytes were
differentiated into THP-1 macrophages using 50 ng/mL phorbol-12-myristate 13acetate (PMA) for 24 h [34]. Subsequently, adherent cells were washed twice with
serum-free medium and rested for another 24 h in PMA-free RPMI + 10% FBS
medium. CD44 expression on THP-1 macrophages was conducted using flow
cytometry following incubation with the CD44-specific antibody (1:1000 dilution) for
1 h followed by cell pelleting and washing the cell pellet with PBS. THP-1 macrophages
were then incubated with DyLight 488 goat anti-mouse IgG at 1:1000 dilution for 30
min. Following cell pelleting and washing, cells were fixed in 4% paraformaldehyde
and cell-associated fluorescence was determined by flow cytometry using BD
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FACSVerse (BD Biosciences). THP-1 macrophages (500,000 cells per well) were
treated with IL-1β (10 ng/mL) or uric acid (10 mg/dL) in serum-free RPMI 1640
medium for 24 h. THP-1 macrophages were washed with PBS, collected, and CD44
expression was determined using flow cytometry as described above.
Cd44+/+ and Cd44−/− male mice (12–14 weeks old, n = 2 in each group) were
euthanized, and isolation and culture of bone marrow derived macrophages (BMDMs)
were performed as previously described using 10 ng/mL M-CSF [52]. BMDMs were
seeded onto cover slips in 6-well plates (500,000 cells per well) and incubated with
MSU crystals (100 μg/mL) for 4 h, followed by cell staining using fluoroshieldmounting medium with DAPI and visualized under a microscope. All animal
experiments were approved by the Institutional Animal Care and Use Committee
(IACUC) at Chapman University.
THP-1 macrophages (500,000 cells per well) were treated with MSU crystals (100
μg/mL) ± HA (100 μg/mL) for 4 h. Subsequently, macrophages were collected,
pelleted, and washed with PBS. MSU phagocytosis was determined by analyzing the
change in cell side-scatter using a flow cytometer. Two regions of interest were
identified: the P1 region representing the THP-1 macrophage population in the absence
of MSU crystal exposure and the P2 region with increased cell side scatter indicative
of MSU phagocytosis. Data are presented as the percentage of cells in the P2 region
across different experimental groups.
Comparative Binding of P6 Peptide and HA Using an enzyme-linked
immunosorbent assay (ELISA) Format
Wells of high-binding microtiter plates were coated with either the P6 peptide or high
molecular weight HA (molecular weight >1 million Da) in serial concentrations
between 1 ng/mL and 1 μg/mL overnight in phosphate buffered saline (PBS) (100 µL
per well) at 4 °C. To remove unbound molecules, wells were washed with PBS + 0.05%
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Tween 20 and subsequently blocked using 2% bovine serum albumin (BSA) (300 µL
per well) for 2 h at room temperature. CD44-IgG Fc fusion protein (R&D Systems) (0.1
µg/mL) in PBS + 0.05% Tween 20 (100 µL per well) was added to both coated and
uncoated wells and incubated for 1 h at room temperature. Following washing with
PBS + 0.1% Tween 20, anti-human IgG Fc-HRP (1:1000) was added and incubated at
room temperature for 1 h, followed by washing three times with PBS + 0.05% Tween
20. Turbo TMB-ELISA substrate solution was added (100 µL per well), and absorbance
intensity was determined at 450 nm. Absorbance values in the P6 peptide and HAcoated wells were subtracted from the absorbance values of uncoated wells to adjust
for any non-specific binding by CD44-IgFc.
CD44-Dependent Association and Internalization of Fluorescein-P6 Peptide in
THP-1 Macrophages
THP-1 macrophages (500,000 cells per well) were treated with different concentrations
of the fluorescein-labeled P6 peptide (1, 10, or 25 μM) for 30 or 60 min, after which
cells were washed with PBS, trypsinized, and fixed using 4% paraformaldehyde. Cellassociated fluorescence was determined by flow cytometry using BD FACSVerse. In a
separate set of experiments, THP-1 macrophages were pretreated with anti-CD44
antibody (2.5 μg/ml) for 1 h prior to the addition of fluorescence-labeled P6 peptide (1,
10 or 25 μM) for 1 h. Cell-associated fluorescence was determined as described above.
THP-1 macrophages (250,000 cells per well) were seeded in 4-well chamber slides
followed by treatment with different concentrations of the fluorescein-labeled P6
peptide (1, 10, or 25 μM) for 6 h. Subsequently, cells were fixed using 4%
paraformaldehyde for 10 min followed by washing with PBS and permeabilization with
0.1% Triton X-100 for 5 min. Following washing with PBS, cells were blocked for 30
min in 2% BSA in PBS. Cells were then incubated with anti-α tubulin monoclonal
antibody (1:1000) for 2 h. Nuclear staining was performed using 4, 6 diamidino-2phenylindole (DAPI). Confocal imaging and Z-stacking were performed using a Nikon
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Ti-E microscope. Intracellular mean fluorescence was determined using three different
fields in each group.
Cytotoxicity of P6 Peptide, Colchicine, and Colchicine-P6 Peptide against THP-1
Macrophages
THP-1 macrophages were plated in a 96-well plate at a density of 1 × 104 per well and
treated with different concentrations of P6 peptide, colchicine, colchicine-P6 peptide
conjugate (1, 10, or 25 μM) for 24 h. Subsequently, 10 μL of CCK-8 solution was added
to each well and absorbance was measured 90 min later at 450 nm. Cytotoxicity was
expressed as the percentage of viable cells following treatments.
Impact of P6 Peptide, Colchicine, and Colchicine-P6 Peptide Treatments on MSU
Phagocytosis by THP-1 Macrophages and Downstream ROS Generation and IL8 Secretion
THP-1 macrophages (500,000 cells per well) were incubated with the P6 peptide,
colchicine, or colchicine-P6 peptide at 1, 10, or 25 μM concentrations for 24 h.
Subsequently, cells were treated with MSU crystals (100 μg/mL) for 4 h. MSU
phagocytosis by THP-1 macrophages was determined using flow cytometry as
described above.
THP-1 macrophages (500,000 cells per well) were treated with MSU crystals (100
μg/mL) for 2, 4, and 6 h. ROS staining solution (1:1000 ratio) was added to the wells
and incubated for 1 h. Subsequently, cells were collected, washed, and cell-associated
fluorescence was determined using flow cytometry. Media were collected at 2, 4, and
6 h, and IL-8 media concentrations were determined by ELISA. In another set of
experiments, THP-1 macrophages were incubated with the P6 peptide, colchicine, or
colchicine-P6 peptide at 1, 10, or 25 μM concentrations for 24 h. Subsequently, cells
were treated with MSU crystals (100 μg/mL) for 6 h. ROS generation and IL-8
concentrations were determined as described above.
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Stability of P6 Peptide in Normal Synovial Fluid (SF) Aspirates
P6 peptide stability in the presence of normal SF from three donors with no history of
arthritis was examined using an analytical reversed-phase High Performance Liquid
Chromatography (RP-HPLC). Using seven microcentrifuge tubes, a total of 50 μL of
normal SF was diluted with 150 μL of PBS in each tube. Following equilibrating diluted
SF to 37 ± 1 °C for 15 min, 50 μL of peptide stock solution (1 mM solution in 100%
sterile water) was added to each tube. Next, at different time intervals (0, 1, 2, 3, 4, 6,
and 24 h), an aliquot of the reaction solution (100 μL) was sampled. Cold methanol
(200 μL) was added to each aliquot in order to precipitate proteins that were present in
the SF. This was followed by cooling the solution to 4 °C for 15 min followed by
centrifugation at 500 g for 15 min to precipitate SF proteins. To determine the
proteolytic stability of the P6 peptide, the supernatant was injected into an analytical
RP-HPLC C18 column. In order to measure the concentration of the P6 peptide isolated
from SF, the area under the curve (AUC) of the P6 peptide at each time point was
estimated using an average of four runs, and normalized to AUC values at time 0 and
expressed as the percentage of AUC at time 0.
Statistical Analyses
Data were derived from at least three independent experiments with a minimum of
duplicate runs per group per experiment. Statistical significance comparing two groups
or multiple groups was assessed by the Student’s t-test or analysis of variance
(ANOVA) followed by post-hoc pairwise comparisons using Tukey’s post-hoc test. A
p value of <0.05 was considered statistically significant.
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Results and Discussion
Synthesis of P6 Peptide
Modified P6 peptide H2N-WYKGDKFLYLQNGIEAIADF-CO-NH2 in reverse order
was assembled on a Fmoc Rink amide resin using Fmoc solid-phase synthesis starting
with Fmoc-Phe-OH). Fmoc deprotection was done by adding 20% piperidine in
Dimethylformamide (DMF) (v/v). The modified version of the P6 peptide may not
exhibit a similar behavior, even if all of the amino acids and side chains in the sequence
are the same. The subsequent Fmoc-protected amino acids were coupled to the peptide
template until the last amino acid Fmoc-Trp(Boc)-OH was coupled. The final Fmoc
deprotection was carried out to make a free N-terminal tryptophan residue for the
conjugation of colchicine as shown in Scheme 1. After finishing the synthesis of the
20-amino acid sequence of the P6 peptide, the linear peptide was confirmed by mass
spectrometry analysis.

Scheme 1. Synthesis of the resin-attached peptide (2), modified P6 peptide (3), and
fluorescein-labeled P6 peptide (4) by solid-phase peptide synthesis.
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Synthesis of Colchicine-Glutaryl Amide Conjugate
Coupling of N-deacetylcolchicine with glutaric anhydride was carried out through
solution-phase

chemistry

in

the

presence

of

anhydrous

tetrahydrofuran,

4-

dimethylaminopyridine (DMAP) and triethylamine (TEA) as a base (Scheme 2). The
compound was used in conjugation with the resin-attached P6 peptide to afford the desired
conjugate with the P6 peptide. The formation of the desired compound was confirmed by
Quadrupole Time-of-flight Mass Spectrometry (Q-TOF) .

Scheme 2. Synthesis of colchicine-glutaryl amide (6) and conjugation of the colchicineglutaryl amide conjugate with the P6 peptide (7).

Synthesis of Colchicine-P6 Peptide Conjugate
The peptide-attached resin was used in the coupling with a colchicine-glutaryl amide
conjugate synthesized by the solution phase chemistry in the presence of PyBOP, HOBt,
and DIPEA. The cleavage cocktail containing Trifluoroacetic acid (TFA), thioanisole, 1,2Ethanedithiol (EDT), and anisole (90:5:3:2 v/v/v/v) was used to cleave the resin and all
side-chain protecting groups from the conjugate. After purification via reversed-phase
High Performance Liquid Chromatography (HPLC) and lyophilization, the structure of the
conjugate was confirmed by high-resolution matrix-assisted laser desorption/ionization
Time of Flight (MALDI-TOF) analysis.
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Synthesis of Fluorescein-Labeled P6 Peptide
Scheme 1 also depicts the chemical reaction between the P6 peptide-attached resin and
5(6)-carboxyfluorescein diisobutyrate. Protected P6 peptide-attached resin was used in the
coupling with 5(6)-carboxyfluorescein diisobutyrate on a solid support in the presence of
PyBOP, HOBt, and DIPEA. After the purification of the crude peptide via reversed-phase
HPLC and lyophilization, the structure of the biotinylated P6 peptide was confirmed by
high-resolution MALDI-TOF analysis.
Characterization of CD44 Receptor Expression on Macrophages, Regulation under
Conditions of Inflammation and Role of CD44 in Modulating Monosodium Urate
(MSU) Crystal Phagocytosis by Macrophages
Human THP-1 macrophages express the CD44 receptor as shown by flow cytometry
(Figure 1A). CD44 surface expression increased when THP-1 macrophages were treated
with IL-1β (10 ng/mL) (p < 0.01) or soluble uric acid (UA; 10 mg/dL) compared to the
untreated control macrophages (Figures 4-1A, B; p < 0.001). The magnitude of
enhancement in the cell surface CD44 protein staining subsequent to IL-1β was
approximately two-fold compared to approximately 3-fold enhancement with UA
treatment. UA treatment increased CD44 protein expression by THP-1 macrophages
compared to IL-1β treatment (Figure 4-1C; p < 0.01,). This is a significant finding as
patients with chronic gout often have persistent hyperuricemia and detectable IL-1β levels
in inflamed joints [47]. Given that the CD44 receptor is upregulated under conditions of
inflammation specific to gout, CD44 is plausibly an attractive candidate for targeting
intracellular therapeutics for intra-articular administration that would otherwise be rapidly
cleared from the joint [41]. We have further investigated the direct role that CD44 may
play in facilitating MSU crystal uptake by macrophages. Bone marrow-derived
macrophages (BMDMs) from CD44 wild-type animals (Cd44+/+) appeared to internalize
MSU crystals to a greater extent when compared to the CD44 knockout (Cd44−/−) animals
(white arrows point to MSU crystals in DAPI-stained BMDMs; Figure 4-1D). This
observation is consistent with the phagocytic role of the CD44 receptor and validates our
earlier observations that PRG4, a CD44 ligand, prevents MSU phagocytosis by
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macrophages [33]. Using flow cytometry to detect MSU phagocytosis via a change in
macrophage cell side-scatter [33], we observed that the CD44 receptor-ligand, HA,
significantly reduced MSU phagocytosis by THP-1 macrophages. Figure 1E depicts the
representative flow cytometry plots of MSU-treated macrophages in the absence or
presence of HA (100 μg/mL). Two regions of interest were identified: the P1 region (red),
which represents the majority of macrophage cell population, and the P2 region (purple)
with increased side-scattering as a result of MSU phagocytosis. MSU treatment appeared
to increase the number of cells in the P2 region while HA co-treatment reduced the number
of cells in the P2 region. We previously validated this indirect phagocytosis assay against
a direct method of assessing crystal uptake by cells using cell counting under the
microscope [33]. The quantitative analysis of the percentage of macrophage cell population
in the P2 region across different experimental groups is shown in Figure 1F. HA
significantly reduced MSU phagocytosis by THP-1 macrophages (Figure 4-1F; p < 0.01).
The efficacy of HA in reducing MSU phagocytosis by macrophages is likely to be due to
its ability to bind the CD44 receptor, resulting in receptor internalization [32]. This
interaction reduced the number of available CD44 surface receptors and thus attenuated
macrophage phagocytic activity against MSU crystals. Taken together, our findings
establish the CD44 receptor as a promising therapeutic target in gout, both through
indirectly interfering with MSU phagocytosis by macrophages and in facilitating the uptake
of small molecules that have an intracellular target in macrophages.
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Figure 4-1
The CD44 receptor is highly expressed on differentiated human THP-1 macrophages, is induced by proinflammatory
cytokine interleukin-1 beta (IL-1β) and soluble uric acid (UA) and is directly involved in the phagocytosis of
monosodium urate (MSU) crystals. * p < 0.001; ** p < 0.01. Data are presented as scatter plots of 3–5 independent
experiments with mean and standard deviations highlighted. (A) A representative flow cytometry plot showing the
expression of CD44 receptor on THP-1 macrophages and the impact of IL-1β (10 ng/mL) treatment on CD44 receptor
protein expression. A rightward shift was observed indicative of increased receptor density on cell surface. (B) A
representative flow cytometry plot showing enhanced CD44 receptor localization on THP-1 macrophages following
treatment with UA (10 mg/mL). (C) CD44 receptor staining was significantly higher in IL-1β and UA-treated
macrophages compared to untreated cells. (D) MSU crystals were detected intracellularly to a greater extent in bone
marrow-derived macrophages (BMDMs) from CD44 competent animals (Cd44+/+) compared to BMDMs from CD44
knockout animals (Cd44−/−). (E) Representative flow cytometry plots depicting increased cell side-scatter of THP-1
macrophages as a result of MSU phagocytosis. Treatment with the CD44 receptor-ligand hyaluronic acid (HA; 100
μg/mL) reduced MSU phagocytosis indicated by a reduction in macrophage cell side scatter. (F) HA treatment
significantly reduced MSU phagocytosis by THP-1 macrophages.
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Comparative Binding of P6 Peptide and HA to CD44 Receptor and CD44 Dependent
Association of P6 Peptide with THP-1 Macrophages
We studied the interaction between the P6 peptide and the CD44 receptor using a
combination of an ELISA binding assay and the association of fluorescein-labeled P6
peptide with THP-1 macrophages. We compared the binding affinity of the P6 peptide to
the CD44 receptor using HA as a positive control. Using a concentration range between 1
ng/mL and 1 μg/mL, the P6 peptide and HA demonstrated a concentration-dependent
binding to the CD44 receptor (500 ng/mL and 1 μg/mL concentrations showed a higher
binding compared to 1 ng/mL; p < 0.001; Figure 4-2A). Furthermore, there was no
significant difference between the P6 peptide and HA’s binding to CD44. Using flow
cytometry, we observed that fluorescein-P6 peptide associates with THP-1 macrophages
over 1 h in a concentration-dependent manner (Figure 4-2B). In addition, pre-incubation
of THP-1 macrophages with an anti-CD44 antibody reduced the association of fluoresceinP6 peptide with THP-1 macrophages (Figure 4-2B). The reduction in cell-associated
fluorescence with the fluorescein-P6 peptide as a result of pre-incubation with anti-CD44
antibody was approximately 50% across the 1, 10, and 25 μM concentrations (Figure 42C). This finding indicates that the association of the P6 peptide with THP-1 macrophages
was dependent on its binding to the CD44 receptor. The lack of the complete inhibition of
P6 peptide association with the macrophages as a result of CD44 antibody-mediated
receptor neutralization may be explained by the competition between the peptide and the
antibody on binding to the receptor and/or the presence of unblocked CD44 receptors, even
with antibody treatment. Nonetheless, other mechanisms of association cannot be ruled
out. One potential surface receptor is the α4β1 integrin receptor to which pro-MMP-9 can
bind [46].
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Figure 4-2
Comparative binding of the P6 peptide and high molecular weight hyaluronic acid (HA) to the recombinant human CD44
receptor using an enzyme-linked immunosorbent assay (ELISA) format and CD44-dependent association of fluoresceinP6 peptide with human THP-1 macrophages. Fluorescein-P6 peptide was incubated with THP-1 macrophages for 60 min
in the absence or presence of an anti-CD44 antibody (Ab; 2.5μg/mL) and cell-associated fluorescence was determined
by flow cytometry. Data are presented as the mean and standard deviation of three independent experiments. * p < 0.001;
** p < 0.01. (A) The P6 peptide and HA exhibited a concentration-dependent binding to the CD44 receptor with no
difference in binding signals between the P6 peptide and HA across all coating concentrations. (B) A representative flow
cytometry plot showing reduced association of the P6 peptide with THP-1 macrophages in the presence of an anti-CD44
Ab. (C) Neutralization of the CD44 receptor significantly reduced the P6 peptide association with THP-1 macrophages.

Concentration-Dependent Internalization of Fluorescein-P6 Peptide in THP-1
Macrophages Using Confocal Microscopy
The P6 peptide rapidly associated with the THP-1 macrophages in a concentrationdependent manner. This is evidenced by the higher mean cell-associated fluorescence
observed with a 25 μM P6 peptide concentration compared to 1 and 10 μM concentrations
(p < 0.001 for both comparisons; Figure4-3A). We detected internalization of the P6
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peptide in the THP-1 macrophages at the 10 and 25 μM concentrations (Figure 4-3B). The
internalization was evident by co-localization of the P6 peptide with the cytoskeleton
marker, α-tubulin. Using z-stacking, the mean intracellular green fluorescence in the THP1 macrophages was determined. Mean intracellular fluorescence intensity was highest with
the 25 μM concentration. In addition, mean intracellular fluorescence intensity of the 10
μM concentration was higher than the corresponding mean intensity of the 1 μM
concentration (Figure 4-3C). Taken together, the P6 peptide is able to associate with THP1 macrophages and is subsequently internalized by macrophages. The mechanism of
association and uptake is CD44-dependent. Therefore, the P6 peptide can be successfully
used to deliver conjugated small molecules into macrophages, especially under conditions
that upregulate CD44 surface expression.

Figure 4-3
Time and concentration-dependent association of the fluorescein-P6 peptide with THP-1 macrophages and internalization
of P6 peptide in macrophages following incubation for 6 h. THP-1 macrophages were counterstained for α-tubulin (red)
and nuclei (blue). Data are presented as scatter plots of three independent experiments with the mean and standard
deviation highlighted. * p < 0.001; *** p < 0.05. (A) Fluorescein-P6 peptide demonstrated a higher association with
THP-1 macrophages at 1 h compared to 30 min incubation and higher association was observed at 25 μM compared to
the 1 and 10 μM concentrations. (B) Representative confocal microscopy images showing fluorescein-P6 peptide (green),
α-tubulin (red), and nuclear (blue) staining in THP-1 macrophages at 6 h. White arrows point to co-localization of the
fluorescein-P6 peptide with α-tubulin, indicating internalization of the P6 peptide by macrophages. (C) The
internalization of the P6 peptide in THP-1 macrophages was higher at the 25 μM concentration compared to the 1 and 10
μM concentrations.
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Cytotoxicity of P6 Peptide, Colchicine, and Colchicine-P6 Peptide Conjugate against
Human THP-1 Macrophages
The impact of P6 peptide conjugation to colchicine on colchicine’s toxicity against THP-1
macrophages is shown in Figure 4-4. Colchicine demonstrated a dose-dependent cytotoxic
effect against macrophages over 24 h. At the lowest concentration (1 μM), macrophage
cell viability was reduced by approximately 50%. At the highest concentration (25 μM),
macrophage cell viability was reduced by approximately 80%. In contrast, the P6 peptide
demonstrated no cytotoxic effect against THP-1 macrophages at the same concentration
range as those of colchicine. At 25 μM, colchicine-P6 peptide treatment resulted in a
numerical reduction in macrophage cell viability by approximately 15%, compared with a
reduction in cell viability of approximately 6% in 10 μM concentration. This numerical
reduction did not reach statistical significance (p = 0.99 for control vs. colchicine-P6
peptide (10 μM); p = 0.48 for control vs. colchicine-P6 peptide (25 μM)). In addition, the
percentage of viable cells in colchicine-P6 peptide-treated macrophages was significantly
higher when compared to corresponding concentrations of colchicine-treated macrophages
(p < 0.001 for all comparisons), and not significantly different from corresponding P6
peptide concentrations (p > 0.05 for all comparisons). The lack of a toxic effect from the
colchicine-P6 peptide conjugate may be explained by the role of the P6 peptide in the
uptake of colchicine by macrophages. Colchicine, due to its lipophilicity, is able to cross
the cell membrane into the cytosol and is thus available to bind and disrupt microtubules
in the cytosol. Colchicine can concentrate in cells due to its high binding affinity toward
microtubules. This is evident by the ability of neutrophils from patients with gout to
concentrate colchicine compared to levels found in patients’ sera [36,37]. Conjugated
colchicine, on the other hand, is internalized by macrophages in a CD44 receptor-mediated
mechanism. The internalization of CD44 with the colchicine-P6 peptide conjugate results
in the formation of an endosome that later fuses with the lysosome [32]. In this uptake
mechanism, colchicine does not concentrate in the cytosol and is thus unavailable to disrupt
the microtubules and consequently interfere with key cellular processes (e.g., ATP
synthesis resulting in cell death) [32,36,37].
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Figure 4-4
Impact of P6 peptide, colchicine, and colchicine-P6 peptide conjugate treatments on human THP-1 macrophage cell
viability at 24 h using the Cell Counting Kit-8 (CCK-8) assay. P6 peptide and colchicine-P6 peptide treatments (1, 10,
and 25 μM) showed no significant difference in cell viability when compared with the control. Colchicine (1, 10, and 25
μM) dose-dependently reduced macrophage cell viability. Data are presented as scatter plots of three independent
experiments with at least duplicate wells per treatment. Mean and standard deviations are highlighted. * p < 0.001; n.s.:
non-significant.

Impact of P6 Peptide, Colchicine, and Colchicine-P6 Peptide Treatments on
monosodium urate (MSU) Crystal Phagocytosis by Human THP-1 Macrophages
The impact of P6 peptide, colchicine, and colchicine-P6 peptide treatments on MSU
phagocytosis by THP-1 macrophages is shown in Figure 5. Following a 4 h incubation,
THP-1 macrophages internalized MSU crystals. P6 peptides (10 and 25 μM) significantly
reduced MSU phagocytosis by THP-1 macrophages (Figure 4-5B; p < 0.001 for both
comparisons). In addition, colchicine-P6 peptide treatments (1, 10, and 25 μM) reduced
MSU phagocytosis to a comparable level as observed with the P6 peptide alone (p < 0.001
against MSU alone; p > 0.05 against MSU + P6 peptide). We also observed that colchicine
treatments (1, 10, and 25 μM) reduced MSU phagocytosis as determined by flow
cytometry. This effect may be related to the cytotoxic effect of colchicine against THP-1
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macrophages. As a significant proportion of macrophages undergo apoptosis due to
colchicine treatment, the number of macrophages available to internalize MSU crystals
would be significantly reduced. As our assay measures the percentage of cells that
internalized MSU crystals out of the whole cell population, it is imperative that the cell
population remains viable. Therefore, it appears that the percentage of positive cells in
colchicine-treated macrophages was artificially lowered due to the toxic effect of
colchicine. The reduction in macrophage MSU phagocytosis with P6 peptide treatment is
consistent with our finding that macrophage CD44 participates in MSU phagocytosis and
that occupying the receptor with a high-molecular weight ligand (e.g., HA, PRG4 or in this
case a small peptide) has a therapeutic effect in conditions of crystal-induced inflammation.
Our findings support that the role of P6 in the colchicine-P6 peptide extends beyond
modulation of colchicine off-target effect on microtubules, but also offers a
pharmacologically-active role in the conjugate.

Figure 4-5
Impact of P6 peptide, colchicine, and colchicine-P6 peptide conjugate treatments on monosodium urate (MSU) crystal
phagocytosis by human THP-1 macrophages. THP-1 macrophages were pre-treated with the P6 peptide, colchicine, or
colchicine-P6 peptide (1, 10, or 25 μM) for 24 h followed by treatment with MSU crystals (100 μg/mL) for 4 h. Data are
presented as scatter plots of three independent experiments with the mean and standard deviation highlighted. * p < 0.001.
(A) Representative flow cytometry plots depicting increased macrophage cell population side-scatter in MSU-treated
THP-1 macrophages, indicative of MSU phagocytosis. Treatments with P6 peptide, colchicine, or P6 peptide-colchicine
(10 μM) appeared to reduce macrophage cell clustering in the P2 region indicative of reduced MSU phagocytosis. (B)
P6 peptide (10 and 25 μM), colchicine (1, 10, and 25 μM) and P6 peptide-colchicine (1, 10, and 25 μM) treatments
reduced MSU phagocytosis by THP-1 macrophages.
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Anti-Inflammatory Efficacy of P6 Peptide, Colchicine, and Colchicine-P6 Peptide
Treatments in MSU-Stimulated THP-1 Macrophages
We initially studied the time-dependent ROS generation and IL-8 secretion following the
incubation of THP-1 macrophages with MSU crystals (100 μg/mL) (Figures 4-6A, B). At
6 h, MSU induced a significant increase in intracellular ROS levels that corresponded to a
significant increase in IL-8 secretion. P6 peptide treatments (10 and 25 μM) reduced ROS
generation and IL-8 secretion (1, 10, and 25 μM) (Figures 4-6C, D; p < 0.001 for all
comparisons against MSU alone). Colchicine-P6 peptide (1 μM and 10 μM) demonstrated
superior efficacy in reducing ROS generation and IL-8 secretion compared to
corresponding P6 peptide concentrations (Figures 4-6C, D; p < 0.001 when comparing
MSU + colchicine-P6 peptide vs. MSU + P6 peptide). The mean estimated reduction in
ROS due to MSU + colchicine-P6 peptide treatment compared to the MSU + P6 peptide
treatment was 27.0% at 10 μM concentration. In addition, the mean estimated reduction in
IL-8 secretion due to MSU + colchicine-P6 peptide treatment compared to MSU + P6
peptide treatment was 43.8% at a 1 μM concentration and 24.2% at a 10 μM concentration.
The enhancement of the P6 peptide’s anti-inflammatory efficacy by colchicine conjugation
was biologically significant at 1 and 10 μM concentrations. Interestingly, this enhancing
effect disappeared at the 25 μM concentration due to the ceiling effect observed with the
P6 peptide effect. Colchicine alone reduced ROS generation (10 and 25 μM) and IL-8
secretion (1, 10, and 25 μM). The superior efficacy of the colchicine-P6 peptide compared
to P6 peptide alone is explained by the colchicine moiety, which in itself possesses the
ability to reduce ROS generation and downstream IL-8 secretion.
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Figure 4-6
Time-dependent impact of monosodium urate (MSU) crystals on the generation of reactive oxygen species (ROS) and
the production of inflammatory chemokine interleukin-8 (IL-8) by human THP-1 macrophages and anti-inflammatory
efficacy of the P6 peptide, colchicine, and colchicine-P6 peptide in MSU stimulated THP-1 macrophages. Treatments
with the P6 peptide, colchicine, and colchicine-P6 peptide (1, 10, and 25 μM) were performed for 24 h followed by the
addition of MSU crystals (100 μg/mL) for 6 h followed by the determination of ROS generation by flow cytometry and
IL-8 production by enzyme-linked immunosorbent assay (ELISA). Data are presented as scatter plots of three
independent experiments with the mean and standard deviation highlighted. * p < 0.001; ** p < 0.01; *** p < 0.05. (A)
MSU increased ROS generation at 4 and 6 h treatments compared to 2 h. (B) MSU increased IL-8 production by THP-1
macrophages at 6 h compared to 2 and 4 h. (C) Colchicine-P6 peptide was more efficacious than the P6 peptide alone at
1 and 10 μM in reducing ROS generation in THP-1 macrophages. (D) Colchicine-P6 peptide was more efficacious than
the P6 peptide alone at 1 and 10 μM in reducing IL-8 production by THP-1 macrophages
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Stability of P6 Peptide in Synovial Fluid (SF) Aspirates from Subjects with no History
of Arthritis
We evaluated the time-dependent impact of normal SF (n = 3) incubation on P6 peptide
stability and determined the half-life of the P6 peptide under this condition. At 1 h of
incubation, the mean percentage of P6 peptide ± standard deviation (S.D.) recovered from
SF was 47.6% ± 38.7% compared to 45.1% ± 14.7% at 2 h, 40.2% ± 28.8% at 3 h, 49.2%
± 7.8% at 4 h, 36.5% ± 6.2% at 6 h, 18.4% ± 1.3% at 12 h, and 6.4% ± 4.1% at 24 h (Figure
4-7). The estimated half-life of the P6 peptide in normal SF was approximately 4 h. In this
regard, the P6 peptide has a longer half-life compared to other peptides that bind surface
antigens on immune cells, which showed a range of half-life values between 10–100 min
in SF [48]. The high variability in the recovery of the P6 peptide from the SF aspirates
might be related to the low number of unique aspirates we studied, coupled with reported
high inter-donor variability [49]. The origin and composition of SF proteins are not entirely
understood. A limited number of studies have attempted to systematically characterize the
proteome of SF [50]. The SF proteome contains proteins secreted from cartilage, synovium,
and proteins that originate from plasma. In fact, SF protein composition shares many
similarities with the protein composition of plasma [50]. Therefore, the turnover of the P6
peptide is likely to be due to an intrinsic tryptic protease activity derived from plasma [51].

Figure 4-7
Time-dependent degradation of P6 peptide following incubation with synovial fluid (SF) aspirates from subjects with no
history of degenerative joint diseases (n=3). Determination of P6 peptide concentrations in SF samples was performed
using an HPLC assay and area under the curve (AUC) of the P6 peptide peak was determined and normalized to the mean
AUC of P6 peptide at baseline (time = 0 hr). The estimated half-life of P6 peptide in normal SF was 4 approximately
hours.
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Conclusions
In this study, we provided evidence supporting that CD44 expression is enhanced under
conditions characteristic of gout and that the CD44 receptor is directly involved in initiating
inflammation by MSU crystals in macrophages via facilitating the phagocytosis of MSU
crystals. A 20 amino acid peptide ligand of CD44, the P6 peptide, showed a similar binding
profile to CD44 as that of HA and the association and internalization of the P6 peptide by
human THP-1 macrophages was CD44-dependent. We successfully synthesized a
colchicine-P6 peptide conjugate with a hydrolyzable glutaryl amide linker. The
conjugation of colchicine to the P6 peptide abolished the cytotoxic effect of colchicine
against THP-1 macrophages at a concentration range between 1 and 25 μM. The
colchicine-P6 peptide reduced MSU phagocytosis by THP-1 macrophages due to the
ability of the P6 peptide moiety to bind CD44, thus attenuating CD44′s role in mediating
MSU phagocytosis. On the other hand, the colchicine-P6 peptide conjugate showed
superior efficacy in reducing ROS generation and IL-8 secretion, potentially due to the
contribution of the colchicine moiety where colchicine was efficacious in reducing ROS
generation and downstream inflammatory chemokine production. The stability of the P6
peptide in normal SF was better than previously reported peptides that bind immune cells
in SF. Taken together, conjugation of colchicine to the P6 peptide minimized the off-target
cytotoxic effect of colchicine and preserved the anti-inflammatory effect of colchicine with
the P6 peptide moiety playing an effector role in reducing MSU phagocytosis and
downstream inflammation in macrophages. The colchicine-P6 peptide is a potential novel
therapeutic in gout and future work will evaluate the kinetics and efficacy of the intraarticular colchicine-P6 peptide in an animal model of acute gouty arthritis. To our
knowledge, this is the first report demonstrating the utility of a colchicine-peptide
conjugate as an anti-inflammatory therapeutic.
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OVERALL CONCLUSION

Gout is a prevalent inflammatory arthritis due to the precipitation of serum uric acid into
crystallized deposits of monosodium urate (MSU) crystals in and around the joint.
Several studies show that inadequate therapeutic management of acute gout is prevalent
and continues to grow. Considering the severe toxicities reported with high-dose colchicine
and other existing anti-inflammatory drugs, there is a significant need to identify novel
pharmacologic targets with the goal of controlling inflammation in acute gout.
CD44 is a highly glycosylated transmembrane receptor with various isoforms generated by
extensive alternative splicing and posttranslational modifications and is widely expressed
in immune and connective tissue cells. In a recent study, we have shown that with using
either a CD44 ligand, e.g. hyaluronic acid or an antibody that induces the shedding of CD44
extracellular domain (ECD), agonist-induced TLR2 activation was suppressed in
macrophages.
We investigated the role of CD44 in mediating MSU crystal induced inflammation in vitro
and in vivo. CD44 mediated the phagocytic uptake of MSU with intracellular translocation
of the receptor as a result of exposure to MSU crystals. Antibody-mediated CD44
extracellular domain shedding reduced MSU phagocytosis in murine and human
macrophages. CD44 extracellular domain shedding also reduced MSU mediated NF-kB
nuclear translocation and pro-IL-1b production. Conversion of procaspase to caspase-1,
caspase-1 activity and secretion of mature IL-1b was also inhibited by antibody-mediated
CD44 extracellular domain shedding. Shedding of the extracellular domain also reduced
LPS mediated priming of PBMCs macrophages with a reduction in -IL-1b production.
CD44 deficiency protected mice from inflammation and recruitment of neutrophils and
monocytes in a model of acute gout. Anti-CD44 treatment abrogated the recruitment of
neutrophils and monocytes and reduced inflammation in the same model.
Moreover, we evaluated the feasibility of conjugating the P6 peptide, a 20-amino acid
residue peptide that binds to CD44, to N-deacetylcolchicine via a hydrolyzable linker and
studied the efficacy and safety of the colchicine-P6 peptide conjugate in an in vitro model

101

of MSU stimulated macrophages. The P6 peptide showed a similar binding profile to CD44
as that of HA and the association and internalization of the P6 peptide by human THP-1
macrophages was CD44-dependent. We successfully synthesized a colchicine-P6 peptide
conjugate with a hydrolyzable glutaryl amide linker. The conjugation of colchicine to the
P6 peptide abolished the cytotoxic effect of colchicine against THP-1 macrophages at a
concentration range between 1 and 25 μM. The colchicine-P6 peptide reduced MSU
phagocytosis by THP-1 macrophages due to the ability of the P6 peptide moiety to bind
CD44, thus attenuating CD44′s role in mediating MSU phagocytosis. On the other hand,
the colchicine-P6 peptide conjugate showed superior efficacy in reducing ROS generation
and IL-8 secretion, potentially due to the contribution of the colchicine moiety where
colchicine was efficacious in reducing ROS generation and downstream inflammatory
chemokine production. Conjugation of colchicine to the P6 peptide minimized the offtarget cytotoxic effect of colchicine and preserved the anti-inflammatory effect of
colchicine with the P6 peptide moiety playing an effector role in reducing MSU
phagocytosis and downstream inflammation in macrophages. Taken together, our findings
establish the CD44 receptor as a promising therapeutic target in gout, both through
inhibition of NFkB pathway activation and modulation of macrophage phagocytosis of
MSU crystals and in facilitating the uptake of small molecules that have an intracellular
target in macrophages.
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